var title_f38_51_39728="Gingival abnormalities";
var content_f38_51_39728=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gingival abnormalities in scurvy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The gingival swelling and dusky color just above two of the teeth indicate hemorrhage into the gums of this patient with poor dentition. The gingival abnormalities of scurvy occur only in the presence of teeth, which presumably provide portals of entry for microbes into the gums. One hypothesis suggests that vitamin C deficiency impairs neutrophil-mediated killing of bacteria, leading to chronic gingivitis, which is then complicated by bleeding from the fragile vessels characteristic of scurvy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hirschmann JV, Raugi GJ. Adult scurvy. J Am Acad Dermatol 1999; 41:895. Copyright &copy;1999 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39728=[""].join("\n");
var outline_f38_51_39728=null;
var title_f38_51_39729="Electrograms intra Hisian block";
var content_f38_51_39729=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Electrophysiologic study in advanced conduction disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tracing, obtained during an electophysiologic study, records three surface ECG lead (1,2, and V1) and the bundle of His electrogram (HBE). The first two sinus beats (SB) are conducted normally from the atrium to the ventricle, but the HBE manifests a split bundle of His electrograms (H and H'). The proximal component (H) is present following a nonconducted P wave (P*), but the distal bundle of His (H') is not activted. The level of atrioventricular block is sharply defined as being intra-Hisian, indicated advanced conduction system disease.",
"    <div class=\"footnotes\">",
"     A: atrial electrogam; V: ventricular electrogram.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39729=[""].join("\n");
var outline_f38_51_39729=null;
var title_f38_51_39730="Osteitis fibrosa cystica findings on x-ray of the phalanges";
var content_f38_51_39730=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Osteitis fibrosa cystica: Findings on x-ray of the phalanges",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A and B) PA Hands. Note the radial margins of the proximal and middle phalanges bilaterally are frayed, irregular, and lace-like (thin arrows) owing to characteristic subperiosteal resorption. Also note the brown tumor (arrowhead) and osteolysis of the distal phalanges (thick arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, Third Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39730=[""].join("\n");
var outline_f38_51_39730=null;
var title_f38_51_39731="Ergonovine: Patient drug information";
var content_f38_51_39731=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ergonovine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/213?source=see_link\">",
"     see \"Ergonovine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13690178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ergonovine Maleate Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bleeding that happens after a birth or an abortion.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ergonovine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High blood pressure, induction of labor or threatened spontaneous abortion.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697309",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mitral disease or diseases of the arteries, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. You may need drugs to lower this side effect. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most often given as a shot into a muscle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695557",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rarely, it will be given into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11642 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39731=[""].join("\n");
var outline_f38_51_39731=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13690178\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021488\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021490\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021489\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021494\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021495\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021497\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021492\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021499\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/213?source=related_link\">",
"      Ergonovine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_51_39732="Ipratropium (oral inhalation): Patient drug information";
var content_f38_51_39732=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ipratropium (oral inhalation): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36469?source=see_link\">",
"     see \"Ipratropium (oral inhalation): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/59/4021?source=see_link\">",
"     see \"Ipratropium (oral inhalation): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8120000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atrovent&reg; HFA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8120001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Atrovent&reg; HFA;",
"     </li>",
"     <li>",
"      Gen-Ipratropium;",
"     </li>",
"     <li>",
"      Mylan-Ipratropium Sterinebs;",
"     </li>",
"     <li>",
"      Novo-Ipramide;",
"     </li>",
"     <li>",
"      Nu-Ipratropium;",
"     </li>",
"     <li>",
"      PMS-Ipratropium;",
"     </li>",
"     <li>",
"      Teva-Ipratropium Sterinebs",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F14943896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to open the airways in lung diseases where spasm may cause breathing problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ipratropium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not to be used to treat intense flare-ups of shortness of breath.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have myasthenia gravis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698371",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throat irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only by a puffer (inhaler) or as a liquid (solution) by a special machine (nebulizer) into the lungs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694373",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A spacer may be used with the puffer (inhaler) for easy use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your puffer (inhaler) use checked with your doctor at each visit. Read and follow facts on how to use the puffer. Make sure you use the puffer the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using more than 1 type of puffer (inhaler), ask your doctor which puffer to use first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse out mouth after each use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12231 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39732=[""].join("\n");
var outline_f38_51_39732=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120000\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120001\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14943896\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031228\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031227\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031232\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031233\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031235\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031230\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031231\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031236\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031237\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/7/21620?source=related_link\">",
"      Ipratropium (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/62/13284?source=related_link\">",
"      Ipratropium (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/45/19155?source=related_link\">",
"      Ipratropium (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36469?source=related_link\">",
"      Ipratropium (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/59/4021?source=related_link\">",
"      Ipratropium (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_51_39733="Calculator: Rheumatoid arthritis Simplified Disease Activity Index (SDAI)";
var content_f38_51_39733=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"RheumatoidArthritisSDAI_form\" name=\"RheumatoidArthritisSDAI_form\" onkeydown=\"clrResults();\" onkeyup=\"RheumatoidArthritisSDAI_fx();\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Rheumatoid arthritis Simplified Disease Activity Index (SDAI)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          SDAI = SJC + TJC +PGA + EGA + CRP",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              CRP",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"CRP_param\" onblur=\"RheumatoidArthritisSDAI_fx(); minMaxCheck();\" onchange=\"RheumatoidArthritisSDAI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"CRP_unit\" onchange=\"RheumatoidArthritisSDAI_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"0.001|0|mcg/dL\">",
"               mcg/dL",
"              </option>",
"              <option value=\"0.1|0|mcg/mL\">",
"               mcg/mL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"              <option value=\"0.0001|0|ng/mL\">",
"               ng/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              PGA",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"PGA_param\" onblur=\"RheumatoidArthritisSDAI_fx(); minMaxCheck();\" onchange=\"RheumatoidArthritisSDAI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"PGA_unit\" onchange=\"RheumatoidArthritisSDAI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|#\">",
"               #",
"              </option>",
"              <option value=\"1|0|index\">",
"               index",
"              </option>",
"              <option value=\"1|0|none\">",
"               none",
"              </option>",
"              <option value=\"1|0|number\">",
"               number",
"              </option>",
"              <option value=\"1|0|points\">",
"               points",
"              </option>",
"              <option value=\"1|0|score\">",
"               score",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              EGA",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"EGA_param\" onblur=\"RheumatoidArthritisSDAI_fx(); minMaxCheck();\" onchange=\"RheumatoidArthritisSDAI_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"EGA_unit\" onchange=\"RheumatoidArthritisSDAI_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|#\">",
"               #",
"              </option>",
"              <option value=\"1|0|index\">",
"               index",
"              </option>",
"              <option value=\"1|0|none\">",
"               none",
"              </option>",
"              <option value=\"1|0|number\">",
"               number",
"              </option>",
"              <option value=\"1|0|points\">",
"               points",
"              </option>",
"              <option value=\"1|0|score\">",
"               score",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              SDAI",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"SDAI_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"SDAI_unit\" onchange=\"RheumatoidArthritisSDAI_fx();\" style=\"width:105px;\">",
"               <option value=\"1|0|#\">",
"                #",
"               </option>",
"               <option value=\"1|0|index\">",
"                index",
"               </option>",
"               <option value=\"1|0|none\">",
"                none",
"               </option>",
"               <option value=\"1|0|number\">",
"                number",
"               </option>",
"               <option value=\"1|0|points\">",
"                points",
"               </option>",
"               <option selected=\"selected\" value=\"1|0|score\">",
"                score",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"RheumatoidArthritisSDAI_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option selected=\"selected\">",
"               1",
"              </option>",
"              <option>",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"0\" cellpadding=\"5\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"80%\">",
"       <tr>",
"        <td align=\"center\" valign=\"top\">",
"         <table border=\"1\" cellpadding=\"10\" class=\"medCalcFontOneBold\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"center\" colspan=\"2\">",
"            <b>",
"             Tender Joint Count",
"            </b>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"left\" valign=\"top\">",
"            <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"medCalcFontOneBold\" summary=\"MedCalc 3000 Table\">",
"             <tr>",
"              <td bgcolor=\"#ffffff\" height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Shoulder",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Elbow",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Wrist",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"9\" height=\"10\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" class=\"tipl\" height=\"20\" width=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"bottom\">",
"               Right hand",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" height=\"20\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\">",
"               <span class=\"medCalcFontTwo\">",
"                MCP 1-5",
"                <br/>",
"                IP 1, PIP 2-5",
"               </span>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"2\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip3\" height=\"30\">",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Knee",
"              </td>",
"             </tr>",
"            </table>",
"           </td>",
"           <td align=\"left\" valign=\"top\">",
"            <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"medCalcFontOneBold\" summary=\"MedCalc 3000 Table\">",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Shoulder&nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Elbow&nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Wrist&nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\" height=\"10\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"bottom\">",
"               Left hand",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tipr\" height=\"20\" width=\"20\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\">",
"               <span class=\"medCalcFontTwo\">",
"                MCP 1-5",
"                <br/>",
"                IP 1, PIP 2-5",
"               </span>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip3\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" colspan=\"2\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Knee&nbsp;",
"               <input name=\"TJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"            </table>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"2\">",
"            TJC &nbsp;",
"            <input name=\"TJC_param\" onfocus=\"blur();\" size=\"3\" type=\"text\"/>",
"            &nbsp;&nbsp;&nbsp;",
"            <input onclick=\"TJCAll();\" type=\"button\" value=\"Select All\"/>",
"            &nbsp;&nbsp;&nbsp;",
"            <input onclick=\"TJCClr();\" type=\"button\" value=\"Clear All\"/>",
"           </td>",
"          </tr>",
"         </table>",
"        </td>",
"        <td align=\"center\" valign=\"top\">",
"         <table border=\"1\" cellpadding=\"10\" class=\"medCalcFontOneBold\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"center\" colspan=\"2\">",
"            <b>",
"             Swollen Joint Count",
"            </b>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"left\" valign=\"top\">",
"            <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"medCalcFontOneBold\" summary=\"MedCalc 3000 Table\">",
"             <tr>",
"              <td bgcolor=\"#ffffff\" height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Shoulder",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Elbow",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Wrist",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"9\" height=\"10\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" class=\"tipl\" height=\"20\" width=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"bottom\">",
"               Right hand",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" height=\"20\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\">",
"               <span class=\"medCalcFontTwo\">",
"                MCP 1-5",
"                <br/>",
"                IP 1, PIP 2-5",
"               </span>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" colspan=\"2\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip3\" height=\"30\">",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td height=\"20\">",
"               <br/>",
"              </td>",
"              <td align=\"left\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"middle\">",
"               &nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;Knee",
"              </td>",
"             </tr>",
"            </table>",
"           </td>",
"           <td align=\"left\" valign=\"top\">",
"            <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"medCalcFontOneBold\" summary=\"MedCalc 3000 Table\">",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Shoulder&nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Elbow&nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\" height=\"5\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Wrist&nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\" height=\"10\">",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\" valign=\"bottom\">",
"               Left hand",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tipr\" height=\"20\" width=\"20\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\">",
"               <span class=\"medCalcFontTwo\">",
"                MCP 1-5",
"                <br/>",
"                IP 1, PIP 2-5",
"               </span>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" width=\"3\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\" width=\"20\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td align=\"center\" bgcolor=\"#cccccc\">",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"              </td>",
"              <td bgcolor=\"#ffffff\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td bgcolor=\"#ffffff\" class=\"tip1\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip3\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" class=\"tip2\" height=\"30\">",
"               <br/>",
"              </td>",
"              <td bgcolor=\"#ffffff\" colspan=\"2\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td colspan=\"9\">",
"               <br/>",
"              </td>",
"             </tr>",
"             <tr>",
"              <td align=\"right\" bgcolor=\"#cccccc\" colspan=\"8\" height=\"20\" valign=\"middle\">",
"               Knee&nbsp;",
"               <input name=\"SJC_box\" onclick=\"RheumatoidArthritisSDAI_fx();\" style=\"height: 12px; width: 12px;\" type=\"checkbox\"/>",
"               &nbsp;",
"              </td>",
"              <td>",
"               <br/>",
"              </td>",
"             </tr>",
"            </table>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"2\">",
"            SJC &nbsp;",
"            <input name=\"SJC_param\" onfocus=\"blur();\" size=\"3\" type=\"text\"/>",
"            &nbsp;&nbsp;&nbsp;",
"            <input onclick=\"SJCAll();\" type=\"button\" value=\"Select All\"/>",
"            &nbsp;&nbsp;&nbsp;",
"            <input onclick=\"SJCClr();\" type=\"button\" value=\"Clear All\"/>",
"           </td>",
"          </tr>",
"         </table>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"      <tr>",
"       <td bgcolor=\"#eeeeee\" width=\"1%\">",
"        <br/>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <span class=\"medCalcFontTitleBox\">",
"         SDAI Interpretation",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"       <tr id=\"rr1_1\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          SDAI &lt;= 3.3:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Remission",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_2\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          SDAI &gt; 3.3 and &lt;= 11:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Low Disease Activity",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_3\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          SDAI &gt; 11 and &lt;= 26:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Moderate Disease Activity",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_4\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          SDAI &gt; 26:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          High Disease Activity",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       In the hands, the joints that are evaluated include the first through fifth metacarpophalangeal joint, the interphalangeal joint of the thumb, and the second through fifth proximal interphalangeal joint.",
"      </li>",
"      <li>",
"       The",
"       <b>",
"        PGA",
"       </b>",
"       or Patient Global disease Activity estimate represents the patient's self assessment of disease activity on a 0-10 scale where 10 means maximal activity.",
"      </li>",
"      <li>",
"       The",
"       <b>",
"        EGA",
"       </b>",
"       or Evaluator Global disease Activity estimate represents the evaluator's assessment of disease activity on a 0-10 scale where 10 means maximal activity.",
"      </li>",
"      <li>",
"       An",
"       <b>",
"        SDAI",
"       </b>",
"       reduction by 7 represents a moderate improvement.  A reduction more than 17 represents a major improvement.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Aletaha D, Ward MM, Machold KP, et. al. Remission and active disease in rheumatoid arthritis:  defining criteria for disease activity states.",
"        <i>",
"         Arthritis Rheum",
"        </i>",
"        . 2005 Sep;52(9):2625-36.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Smolen JS, Breedveld FC, Schiff MH, et. al. A simplified disease activity index for rheumatoid arthritis for  use in clinical practice.",
"        <i>",
"         Rheumatology (Oxford)",
"        </i>",
"        . 2003 Feb;42(2):244-57.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39733=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function RheumatoidArthritisSDAI_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.RheumatoidArthritisSDAI_form){",
"",
"",
"doCalc = true;",
"if (CRP_param.value.indexOf(',') >= 0){ CRP_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(CRP_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = CRP_unit.options[CRP_unit.selectedIndex].value.split('|');",
"CRP = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (PGA_param.value.indexOf(',') >= 0){ PGA_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(PGA_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = PGA_unit.options[PGA_unit.selectedIndex].value.split('|');",
"PGA = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (EGA_param.value.indexOf(',') >= 0){ EGA_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(EGA_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = EGA_unit.options[EGA_unit.selectedIndex].value.split('|');",
"EGA = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"TJC = 0;",
"for (jcount = 0; jcount < 28; jcount++){",
"if(TJC_box[jcount].checked) TJC = TJC + 1;",
"}",
"TJC_param.value = TJC;",
"SJC = 0;",
"for (jcount = 0; jcount < 28; jcount++){",
"if(SJC_box[jcount].checked) SJC = SJC + 1;",
"}",
"SJC_param.value = SJC;",
"dp = decpts.options[decpts.selectedIndex].text;",
"SDAI =  SJC + TJC +PGA + EGA + CRP;",
"",
"unit_parts = SDAI_unit.options[SDAI_unit.selectedIndex].value.split('|');",
"if (doCalc) SDAI_param.value = fixDP((SDAI - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"if (doCalc){",
"",
"rrclr();",
"if (SDAI <= 3.3){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((SDAI > 3.3) && (SDAI <= 11)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if ((SDAI > 11) && (SDAI <= 26)){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"if (SDAI > 26){ document.getElementById('rr1_4').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.RheumatoidArthritisSDAI_form){",
"",
"if (CRP_param.value && CRP < 0.1) {",
"CRP = 0;",
"CRP_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for CRP is 0.1 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (CRP_param.value && CRP > 10) {",
"CRP_param.value = \"\";",
"clrResults();",
"CRP = 0;",
"doCalc = false;",
"alert(\"The maximum value for CRP is 10 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (PGA_param.value && PGA < 0) {",
"PGA = 0;",
"PGA_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for PGA is 0 #.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (PGA_param.value && PGA > 10) {",
"PGA_param.value = \"\";",
"clrResults();",
"PGA = 0;",
"doCalc = false;",
"alert(\"The maximum value for PGA is 10 #.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (EGA_param.value && EGA < 0) {",
"EGA = 0;",
"EGA_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for EGA is 0 #.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (EGA_param.value && EGA > 10) {",
"EGA_param.value = \"\";",
"clrResults();",
"EGA = 0;",
"doCalc = false;",
"alert(\"The maximum value for EGA is 10 #.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.RheumatoidArthritisSDAI_form){",
"",
"SDAI_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"function TJCClr() {",
"with(document.RheumatoidArthritisSDAI_form){",
"TJC = 0;",
"for (jcount = 0; jcount < 28; jcount++){",
"TJC_box[jcount].checked = false;",
"}",
"TJC_param.value = TJC;",
"RheumatoidArthritisSDAI_fx();",
"}}",
"",
"",
"function TJCAll() {",
"with(document.RheumatoidArthritisSDAI_form){",
"TJC = 28;",
"for (jcount = 0; jcount < 28; jcount++){",
"TJC_box[jcount].checked = true;",
"}",
"TJC_param.value = TJC;",
"RheumatoidArthritisSDAI_fx();",
"}}",
"",
"function SJCClr() {",
"with(document.RheumatoidArthritisSDAI_form){",
"SJC = 0;",
"for (jcount = 0; jcount < 28; jcount++){",
"SJC_box[jcount].checked = false;",
"}",
"SJC_param.value = SJC;",
"RheumatoidArthritisSDAI_fx();",
"}}",
"",
"",
"function SJCAll() {",
"with(document.RheumatoidArthritisSDAI_form){",
"SJC = 28;",
"for (jcount = 0; jcount < 28; jcount++){",
"SJC_box[jcount].checked = true;",
"}",
"SJC_param.value = SJC;",
"RheumatoidArthritisSDAI_fx();",
"}}",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f38_51_39733=null;
var title_f38_51_39734="Management of pulmonary sequelae and complications of coccidioidomycosis";
var content_f38_51_39734=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of pulmonary sequelae and complications of coccidioidomycosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/51/39734/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39734/contributors\">",
"     John N Galgiani, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39734/contributors\">",
"     Shari L Meyerson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/51/39734/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39734/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/51/39734/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39734/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/51/39734/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately two-thirds of persons experience few or no symptoms following respiratory exposure to arthroconidia of Coccidioides spp. Those who become ill typically develop symptoms, such as cough, pleurisy, fever, and weight loss, one to three weeks after exposure; these symptoms generally resolve over the ensuing several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Marked fatigue, one of the common manifestations of the primary infection, may be especially prolonged and slow to resolve. Whether or not the primary exposure is recognized, most infections are self-limited without additional events or complications.",
"   </p>",
"   <p>",
"    Occasional patients have persistent pulmonary consequences of coccidioidomycosis that require medical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical management, and these will be reviewed here. There are three major persistent pulmonary manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Residual pulmonary nodules",
"     </li>",
"     <li>",
"      Coccidioidal cavities",
"     </li>",
"     <li>",
"      Diffuse reticulonodular pneumonia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Primary and disseminated coccidioidomycosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/425?source=see_link\">",
"     \"Primary coccidioidal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26807?source=see_link\">",
"     \"Manifestations and treatment of extrapulmonary coccidioidomycosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17271?source=see_link\">",
"     \"Coccidioidal meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RESIDUAL PULMONARY NODULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In approximately 4 percent of patients with primary coccidioidal pneumonia, infiltrates do not completely resolve; these radiographic findings may persist for months to years following the disappearance of symptoms. These lesions range up to several centimeters in diameter, are often solitary, and are frequently located in the periphery of the lung close to or abutting the pleura.",
"   </p>",
"   <p>",
"    If known to be the consequence of an initial coccidioidal infection, a residual nodule usually poses no problems and requires no treatment. In many cases, however, coccidioidal nodules are discovered incidentally and may be impossible to distinguish from malignancy without invasive evaluation.",
"   </p>",
"   <p>",
"    Testing for anticoccidioidal antibodies is useful. Since these tests become negative in most patients whose pulmonary lesions completely resolve, a positive result is likely to indicate that the lung lesion represents coccidioidomycosis. However, standard tests for anticoccidioidal antibodies are negative in more than 65 percent of patients with coccidioidal nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13751?source=see_link\">",
"     \"Laboratory diagnosis of coccidioidomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If malignancy cannot be excluded, the nodule should be sampled for microscopic examination, either by percutaneous aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/4\">",
"     4",
"    </a>",
"    ] or by transbronchial biopsy. If such procedures are not possible or are unsuccessful, then the nodule should be surgically resected in order to perform histopathological examination, including stains for fungal organisms and culture (",
"    <a class=\"graphic graphic_picture graphicRef77193 graphicRef64404 \" href=\"mobipreview.htm?33/35/34360\">",
"     picture 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75250 graphicRef55301 graphicRef68068 \" href=\"mobipreview.htm?39/36/40522\">",
"     picture 2A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/34/14888?source=see_link\">",
"     \"Differential diagnosis and evaluation of multiple pulmonary nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Percutaneous aspiration of coccidioidal pulmonary nodules does not pose a significant risk of creating a granulomatous track to the skin or reactivating clinical disease within the lesion. Resection of nodules can most often be accomplished by a minimally invasive approach using thoracoscopy and typically involves en block resection with generous margins of normal lung, anticipating the possibility that the lesion is malignant. The thoracoscopic approach has low morbidity with an average hospital stay of one day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis has been established, further treatment of a residual coccidioidal nodule in an otherwise asymptomatic patient is typically unnecessary. A more difficult management decision arises when reactivation of residual infection occurs, due to lesion disruption in the setting of either incomplete surgical resection or percutaneous biopsy. This may lead to formation of a local abscess or fistula.",
"   </p>",
"   <p>",
"    There are no published data on how to manage incomplete resection. One approach is to treat the patient postoperatively with an oral antifungal agent such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    for three to six months at a dose of 400 mg per day (200 mg twice daily with itraconazole) to prevent local complications. Ketoconazole is less well tolerated and therefore less often used.",
"   </p>",
"   <p>",
"    If local complications occur,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , with or without local debridement, is reasonable. Optimal management may require consultation with infectious disease specialists and thoracic surgeons familiar with this problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COCCIDIOIDAL CAVITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cavities occur in approximately 2 to 8 percent of coccidioidal infections in adults but are rare in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/5\">",
"     5",
"    </a>",
"    ]. Half of these cavities will resolve within the first two years.",
"   </p>",
"   <p>",
"    There are three types of coccidioidal cavities: thin-walled, ruptured, and chronic fibrocavitary pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thin-walled cavities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammatory pulmonary process that develops during the initial coccidioidal infection results in areas of infarction that leads to cavitation in some patients. A cavity can also occur when a previously stable coccidioidal nodule liquefies and erodes into a bronchiole. These cavities often have the same dimensions as the original nodule.",
"   </p>",
"   <p>",
"    Residual cavities are commonly solitary and peripheral in location on chest x-ray. Their walls are often thin with little or no discernible surrounding infiltrate. In the absence of symptoms, treatment is not recommended. Since it is possible for coccidioidal cavities to change appearance, repeat chest x-rays at intervals ranging from six months to two years are helpful to determine whether the lesion is enlarging or regressing. Sequential posterior-anterior and lateral chest x-rays are often sufficient for assessment without the need for multiple CT scans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although thin-walled coccidioidal cavities are usually asymptomatic, symptoms such as pleural discomfort and hemoptysis may occur. Such symptoms often improve with oral antifungal agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    ) but may return if treatment is discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical resection is rarely indicated because of the efficacy of oral azoles. Resection is most often considered in young, otherwise healthy patients whose symptoms persist or recur after a one to two-year trial of azoles. CT imaging should be performed prior to surgery in order to detect satellite lesions that may not have been recognized on chest x-ray.",
"   </p>",
"   <p>",
"    Although surgical resection may be curative, it can be technically difficult. If the lesion is peripheral, there are often extensive adhesions within the pleura. More central and more acutely inflamed lesions will have a significant area of inflamed lung surrounding the cavity, which is generally underappreciated on CT scan. This often mandates large wedge resections and even lobectomy to obtain an adequate margin to allow stapling in an area of relatively normal parenchyma. Careful attention must be paid not to enter or rupture the cavity since this can lead to spread throughout the pleural space and possible empyema. Thus, the experience of the surgeon is an important consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ruptured cavities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite their frequent proximity to the pleura, it is surprisingly uncommon for coccidioidal cavities to rupture into the pleural space. When rupture does occur, a bronchopleural fistula is formed. Dyspnea and chest pain are the most common manifestations, suggesting a pneumothorax. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ruptured coccidioidal cavities are most frequent in young, otherwise healthy, athletic males and are not associated with immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/6\">",
"     6",
"    </a>",
"    ]. Symptoms associated with rupture are the first symptoms of the coccidioidal infection in approximately one-half of cases.",
"   </p>",
"   <p>",
"    On chest x-ray, a ruptured cavity appears as a pneumothorax with an associated effusion with an air-fluid level. Since a spontaneous pneumothorax does not normally produce an effusion, this finding is helpful in diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a ruptured coccidioidal cavity is promptly diagnosed, the preferred therapy is surgical resection of the cavity, often requiring lobectomy due to the surrounding inflammation, and decortication to facilitate reexpansion of the remaining lung. This allows maximum preservation of lung function. If the diagnosis is delayed for one week or more, surgical repair becomes a progressively greater technical challenge and resection may not be technically possible. In this case, consideration should be given to decortication without attempt at resection, accepting the need for longer term chest tubes. With oral antifungal therapy, many cavities will respond to the point that the air leak resolves and chest tubes can be removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chronic fibrocavitary pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In occasional patients, primary coccidioidal pneumonia does not resolve and evolves into a chronic pulmonary process. Diabetic patients are significantly more likely to develop this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic coccidioidal infections can cause constitutional symptoms (night sweats, fatigue, and weight loss)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    local symptoms (chest pain, hemoptysis, sputum production, shortness of breath). Chest radiography usually shows complex mixtures of infiltrates and cavitation, and hilar adenopathy is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with chronic fibrocavitary pneumonia require treatment, usually with oral antifungal azoles for at least one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/2\">",
"     2",
"    </a>",
"    ]. A randomized trial of 198 patients with chronic pulmonary, soft tissue, or skeletal coccidioidal infections directly compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (400 mg PO once daily) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg PO twice daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/8\">",
"     8",
"    </a>",
"    ]. The two drugs were equivalent in the overall analysis and in the subset with chronic pulmonary infections (eg, response in 63 and 66 percent at 12 months).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    has been less well studied, but has shown promise in a small open-label trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/9\">",
"     9",
"    </a>",
"    ] and as salvage therapy in patients with chronic pulmonary coccidioidomycosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. A small retrospective study of patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or posaconazole for the treatment of refractory coccidioidomycosis showed that many, but not all, patients treated with one of these agents experienced improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/11\">",
"     11",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    can be used for refractory infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26807?source=see_link&amp;anchor=H5#H5\">",
"     \"Manifestations and treatment of extrapulmonary coccidioidomycosis\", section on 'Antifungal drug selection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFUSE RETICULONODULAR PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse reticulonodular pneumonia most often results from fungemia producing multiple septic pulmonary emboli and usually occurs in patients with cellular immune deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/12\">",
"     12",
"    </a>",
"    ]. A similar radiographic appearance can be seen after inhalational exposure to a high density of fungal spores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/13\">",
"     13",
"    </a>",
"    ]. Such patients are typically not immunocompromised.",
"   </p>",
"   <p>",
"    Patients with diffuse reticulonodular pneumonia from coccidioidomycosis are often markedly dyspneic at rest or with minimal exertion. Associated symptoms frequently include fever and night sweats over a period of several days to weeks.",
"   </p>",
"   <p>",
"    Because of the extent of lung involvement, aggressive diagnostic measures are often pursued early. Specimens of bronchoalveolar washings stained for either cytologic examination or fungal organisms may reveal spherules of Coccidioides spp. Fungal cultures of such material are more sensitive but may take several days before growth is evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/14\">",
"     14",
"    </a>",
"    ]. Serologic evidence of infection may also be helpful but can be negative in as many as one-third of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39734/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with diffuse reticulonodular coccidioidal pneumonia is usually begun with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily. An alternate approach is to give a lipid formulation of intravenous amphotericin B (3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily), especially in patients with risk factors for nephrotoxicity. Although there are no comparative studies to indicate whether amphotericin B is more effective than oral azole therapy, some authorities believe that the onset of action of amphotericin B deoxycholate may be faster and thus preferable for initial therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An increasingly preferred alternative strategy is to change therapy following clinical improvement from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    to an oral azole, which is usually continued for at least one year and indefinitely in patients with ongoing immunodeficiency.",
"   </p>",
"   <p>",
"    The treatment approach is the same in immunocompetent patients who have diffuse reticulonodular coccidioidal pneumonia as a result of an inhalational exposure, except that the transition to oral azole therapy may occur sooner and the duration of treatment is shorter compared with patients who develop disease following hematogenous spread. In such patients, treatment can generally be stopped after a minimum of one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/19/13617?source=see_link\">",
"       \"Patient information: Valley Fever (coccidioidomycosis) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Almost all patients exposed to the arthroconidia of Coccidioides spp are asymptomatic or develop symptoms that are self-limited. The occasional pulmonary consequences of coccidioidomycosis include residual pulmonary nodules, coccidioidal cavities, chronic and progressive fibrocavitary pneumonia, and diffuse reticulonodular pneumonia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Residual pulmonary nodules usually have no clinical consequences and require no treatment. If residual pulmonary nodules are discovered incidentally, prior chest x-rays should be obtained to look for a previously detected lesion to assess stability, and serologies for anti-coccidioidal antibodies should be sent. If malignancy cannot be excluded, the nodule should be aspirated percutaneously or surgically resected for histopathological examination and culture. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Residual pulmonary nodules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Residual thin-walled cavities are typically asymptomatic and require no treatment. Periodic imaging may be used to monitor residual cavities. Treatment is recommended if symptoms, such as pleural discomfort and hemoptysis, occur. Such symptoms often improve when treated with oral antifungal agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      ) but relapse may be seen when treatment is discontinued. Surgical resection may be necessary in patients with persistent symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Thin-walled cavities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a cavity ruptures, a bronchopleural fistula results. If promptly diagnosed, surgical resection of the cavity is the preferred approach. If the diagnosis is delayed for one week or more, surgical resection becomes increasingly challenging with a much higher risk of complications; decortication without resection but with long-term chest tubes should be considered. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ruptured cavities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who develop chronic fibrocavitary pneumonia, we recommend treatment with oral antifungal azoles for at least one year.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      (400 mg per day) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (200 mg twice daily) appear to be equivalent in efficacy.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      can be used for refractory infections unresponsive to oral therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chronic fibrocavitary pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For diffuse reticulonodular pneumonia in patients who are immunocompromised, we recommend initial treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      and, following clinical improvement, switching to oral azole therapy and continuing this indefinitely. Occasionally, diffuse reticulonodular pneumonia can occur in an immunocompetent host after exposure to a high density of fungal spores. The treatment approach is the same as in those with disease due to hematogenous spread except that the transition to oral azole therapy can occur earlier and the treatment can generally be stopped after a minimum of one year. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diffuse reticulonodular pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/1\">",
"      Kerrick SS, Lundergan LL, Galgiani JN. Coccidioidomycosis at a university health service. Am Rev Respir Dis 1985; 131:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/2\">",
"      Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005; 41:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/3\">",
"      Read CT. Coin lesion, pulmonary: in the Southwest. (Solitary pulmonary nodules). Ariz Med 1972; 29:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/4\">",
"      Chitkara YK. Evaluation of cultures of percutaneous core needle biopsy specimens in the diagnosis of pulmonary nodules. Am J Clin Pathol 1997; 107:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/5\">",
"      SMITH CE, BEARD RR, SAITO MT. Pathogenesis of coccidioidomycosis with special reference to pulmonary cavitation. Ann Intern Med 1948; 29:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/6\">",
"      Cunningham RT, Einstein H. Coccidioidal pulmonary cavities with rupture. J Thorac Cardiovasc Surg 1982; 84:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/7\">",
"      Santelli AC, Blair JE, Roust LR. Coccidioidomycosis in patients with diabetes mellitus. Am J Med 2006; 119:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/8\">",
"      Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000; 133:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/9\">",
"      Catanzaro A, Cloud GA, Stevens DA, et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007; 45:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/10\">",
"      Stevens DA, Rendon A, Gaona-Flores V, et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007; 132:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/11\">",
"      Kim MM, Vikram HR, Kusne S, et al. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis 2011; 53:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/12\">",
"      Ampel NM, Ryan KJ, Carry PJ, et al. Fungemia due to Coccidioides immitis. An analysis of 16 episodes in 15 patients and a review of the literature. Medicine (Baltimore) 1986; 65:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/13\">",
"      Werner SB, Pappagianis D, Heindl I, Mickel A. An epidemic of coccidioidomycosis among archeology students in northern California. N Engl J Med 1972; 286:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/14\">",
"      DiTomasso JP, Ampel NM, Sobonya RE, Bloom JW. Bronchoscopic diagnosis of pulmonary coccidioidomycosis. Comparison of cytology, culture, and transbronchial biopsy. Diagn Microbiol Infect Dis 1994; 18:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39734/abstract/15\">",
"      Fish DG, Ampel NM, Galgiani JN, et al. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore) 1990; 69:384.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2444 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39734=[""].join("\n");
var outline_f38_51_39734=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RESIDUAL PULMONARY NODULES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COCCIDIOIDAL CAVITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thin-walled cavities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ruptured cavities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chronic fibrocavitary pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFUSE RETICULONODULAR PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2444\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2444|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/20/9539\" title=\"picture 1A\">",
"      Coccidioidomycosis silver stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/31/18932\" title=\"picture 1B\">",
"      Coccidioidomycosis granulomata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/21/4438\" title=\"picture 2A\">",
"      Cocci lung stain A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/57/6040\" title=\"picture 2B\">",
"      Cocci lung stain B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/26/30117\" title=\"picture 2C\">",
"      Cocci lung stain C",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17271?source=related_link\">",
"      Coccidioidal meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/34/14888?source=related_link\">",
"      Differential diagnosis and evaluation of multiple pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13751?source=related_link\">",
"      Laboratory diagnosis of coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26807?source=related_link\">",
"      Manifestations and treatment of extrapulmonary coccidioidomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/19/13617?source=related_link\">",
"      Patient information: Valley Fever (coccidioidomycosis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_51_39735="Oral candidiasis - palate";
var content_f38_51_39735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61040%7EID%2F75887%7EID%2F79519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61040%7EID%2F75887%7EID%2F79519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral candidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White papules and plaques are present on the palate and tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oropharyngeal candidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The buccal mucosa is involved here in the pseudomembranous form of oropharyngeal candidiasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol A Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candida denture stomatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients with dentures, candida stomatitis frequently causes erythematous lesions on the hard palate without pseudomembranes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth Shay, DDS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39735=[""].join("\n");
var outline_f38_51_39735=null;
var title_f38_51_39736="Acne mixed type";
var content_f38_51_39736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68412%7EDERM%2F70809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68412%7EDERM%2F70809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflammatory and noninflammatory acne",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The face of this teenager shows open and closed comedones, papules, and pustules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflammatory acne",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules and pustules are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39736=[""].join("\n");
var outline_f38_51_39736=null;
var title_f38_51_39737="Periprocedural myocardial infarction following percutaneous coronary intervention";
var content_f38_51_39737=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Periprocedural myocardial infarction following percutaneous coronary intervention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/51/39737/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39737/contributors\">",
"     David P Faxon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39737/contributors\">",
"     David R Holmes, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39737/contributors\">",
"     David A Morrow, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/51/39737/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39737/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39737/contributors\">",
"     Allan S Jaffe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/51/39737/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39737/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/51/39737/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous coronary intervention (PCI) is associated with a small, but significant, incidence of serious procedural complications such as death, stroke life threatening bleeding or large myocardial infarction (MI). Periprocedural myocardial necrosis, which can range from a minor elevation of cardiac enzymes to a large myocardial infarction (MI), is the most common complication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With advances in technology, particularly the use of coronary stents, the incidence of early, major cardiac events of death and large myocardial infarction (both non-ST and ST elevation MI) have fallen to less than 3 percent, even in complex multivessel PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, the frequency with which any periprocedural MI is detected has increased especially with the development of sensitive biomarkers of myocardial",
"    <span class=\"nowrap\">",
"     damage/necrosis.",
"    </span>",
"   </p>",
"   <p>",
"    This topic will discuss the risk factors for as well as the incidence, diagnosis, prognosis, mechanisms, prevention and treatment of periprocedural MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum creatinine kinase (CK)-MB after an uncomplicated PCI is elevated in 1 to 38 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/3-10\">",
"     3-10",
"    </a>",
"    ], and elevations more than three times the upper limit of normal (ULN), which is considered to represent an infarction large enough to be associated with short-term complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/6\">",
"     6",
"    </a>",
"    ], in 7 to 18 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/5,10-12\">",
"     5,10-12",
"    </a>",
"    ]. In the American College of Cardiology-National (US) Cardiovascular Data Registry (NCDR) there were over 200,000 patients without an acute coronary syndrome (ACS) or elevated baseline biomarkers who underwent PCI between January 2004 and March 2007. Of these, 8 percent had a peak CK-MB &gt;3 X ULN.",
"   </p>",
"   <p>",
"    An elevation of cardiac troponin above the upper limits of normal following PCI has been noted in as many as 50 percent of patients undergoing PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/3,5,13,14\">",
"     3,5,13,14",
"    </a>",
"    ]. Cardiac troponins are a more sensitive marker than CK-MB for minor degrees of myocardial damage and elevated values after PCI with or without stenting are more common than increases in serum CK-MB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. In an analysis from the Mayo Clinic PCI registry, approximately 20 percent of patients with normal pre-procedural CK-MB and cardiac troponin T (cTnT) values had an isolated postprocedural elevation in serum cTnT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCI may lead to myocardial injury with cell necrosis due to periprocedural events such as coronary dissection, occlusion of a major coronary artery or a side-branch, disruption of collateral flow, slow flow or no-reflow, distal embolization, and microvascular plugging. In patients with PCI related myocardial injury, cardiac troponin (CTn) values will rise. The more sensitive the cTn test used, the higher the percentage of patients who will be labeled as having myocardial injury. The level of myocardial injury (cTn value) that should qualify as a periprocedural myocardial infarction has been debated for many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/18-27\">",
"     18-27",
"    </a>",
"    ]. Two issues have caused significant discussion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The value of cTn above which an MI would be said to have occurred (in patients with normal baseline values). The tension in this area is attributable in large part to the fact that a definition that allows for a high degree of sensitivity for the diagnosis of myocardial necrosis will likely have a low specificity for the prediction of clinically meaningful events; the converse is also true. Unlike a type I MI (acute coronary syndrome), many experts have recommended that a diagnosis of a periprocedural MI be made only if the level of the biomarker is associated with a worse outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/20\">",
"       20",
"      </a>",
"      ]. Their concern is that small increases from baseline in biomarker levels after PCI are expected (microembolization is an example) and do not necessarily represent a complication or a condition for which management needs to change.",
"     </li>",
"     <li>",
"      The difficulty in interpreting post-procedure elevations in patients with elevated baseline values of cTn.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2012 Third Universal Definition of Myocardial Infarction formulated by a joint European Society of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/World",
"    </span>",
"    Health Federation task force arrived at the following definition, which addresses these two (and other) concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/28\">",
"     28",
"    </a>",
"    ]: Myocardial infarction associated with PCI is arbitrarily defined by elevation of cTn values &gt;5 x 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile upper reference limit (URL) in patients with normal baseline values (&le;99",
"    <sup>",
"     th",
"    </sup>",
"    percentile URL) or a rise of cTn values &gt;20 percent if the baseline values are elevated and are stable or falling. In addition, either (i) symptoms suggestive of myocardial ischemia, or (ii) new ischemic electrocardiographic changes or new left bundle branch block, or (iii) angiographic loss of patency of a major coronary artery or a side branch or persistent slow- or no-flow or embolization, or (iv) imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality are required.",
"   </p>",
"   <p>",
"    The task force also made the following recommendation: When a cTn value is elevated but &le;5x99th percentile URL after PCI and the cTn value was normal before the PCI, or when the cTn value is &gt;5x99th percentile URL in the absence of ischemic, angiographic, or imaging findings, the term &ldquo;myocardial injury&rdquo; should be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     New Q waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of new pathological Q waves occurs in approximately 0.5 percent of PCI cases and is usually due to acute stent thrombosis (also called abrupt closure in the absence of a stent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biomarkers of cardiac injury (troponin or CK-MB) can be elevated after PCI, as a consequence of PCI or an elevation present before PCI. The available evidence, in the aggregate, suggests that biomarker elevation before PCI is the more important determinant of long-term mortality, while both might play a role in in-hospital mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=see_link&amp;anchor=H2#H2\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Predictors of mortality and major complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Evidence from elevated CK-MB studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although current guidelines recommend troponin as preferred to CK-MB for diagnosis of MI in all instances, including periprocedural, the majority of studies that evaluated the prognosis of periprocedural biomarker elevation have used CK-MB. The following studies illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a post hoc analysis of the 7773 patients with non-ST elevation acute coronary syndromes in whom PCI was performed in the ACUITY trial, the one year outcomes of the 6 percent of patients who developed periprocedural MI were compared to those without periprocedural MI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link&amp;anchor=H33#H33\">",
"       \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\", section on 'Bivalirudin'",
"      </a>",
"      .) Periprocedural MI was defined as a CK-MB &gt;3x ULN within 24 hours after PCI. After multivariable analysis (adverse baseline and angiographic characteristics, including elevated baseline CK-MB), there was no significant difference in one-year mortality comparing patients to those without periprocedural MI (hazard ratio 1.3, 95% CI 0.85-1.98).",
"     </li>",
"     <li>",
"      A report from the EVENT registry of unselected patients undergoing PCI evaluated the relationship between periprocedural MI (defined as a peak CK-MB &gt;3 X ULN) and one year mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/11\">",
"       11",
"      </a>",
"      ]. After excluding patients with elevated pre-PCI CK-MB and ST-elevation MI, there were 5961 patients. After multivariable adjustment periprocedural MI was independently associated with one-year mortality (adjusted hazard ratio 1.84, 95% CI 1.17-2.89). However, in a time-period specific analysis, the adjusted hazard ratio was significantly greater only for 30-day mortality, but not between one month and one year.",
"     </li>",
"     <li>",
"      Over 60 studies have shown that the greater the elevation of CK-MB after the PCI (either PTCA or stenting), the greater the subsequent mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/5,6,13,29-36\">",
"       5,6,13,29-36",
"      </a>",
"      ]. While elevations of more than 8 and 10-fold the upper limit of normal (ULN) have been associated with increased death or death and MI, the evidence on the impact of lesser degrees of elevation (&gt;1x to &gt;3x ULN) on mortality is less robust [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/5,13,30-36\">",
"       5,13,30-36",
"      </a>",
"      ]. In these studies, the baseline CK-MB was taken into account. However, it appears that the critical level is the pre-PCI cTn value, which, because cTn is so much more sensitive than CK-MB, is often elevated. If it is increasing, although it is more difficult to observe, the CK-MB value is also increasing.",
"     </li>",
"     <li>",
"      In a study of 3687 patients with stable disease who underwent stenting, the mortality rates using the Universal Definition did not increase at up to two years with elevation of the CK-MB, including values &gt;10X upper limit of normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/37\">",
"       37",
"      </a>",
"      ]. However, this study is limited by the lack of use of the 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile as the cut-point.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If one uses the appropriate cut-off value of the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile URL in the analysis, the prognostic importance of pre-PCI elevations is substantial and renders the post-PCI values of substantially less importance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/21\">",
"     21",
"    </a>",
"    ]. Unfortunately, only one study has used this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/14\">",
"     14",
"    </a>",
"    ]. In that study, there was marginal significance to the short-term prognosis driven by mostly non-cardiac events. A 2012 report indicates that it may be possible to define criteria for a declining and then rising pattern of CK-MB that identifies peri-PCI myocardial injury associated with adverse events in the long term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/23\">",
"     23",
"    </a>",
"    ]. Additional details concerning the metrics of this approach and analysis are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Evidence from elevated troponin studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results with troponin have been conflicting with some studies showing long-term prognostic significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/38-40\">",
"     38-40",
"    </a>",
"    ] and others not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/17,31,41,42\">",
"     17,31,41,42",
"    </a>",
"    ]. We believe the following studies provide the best evidence of the relationship between a periprocedural rise in troponin and subsequent mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of fifteen studies including over 7500 patients with normal baseline troponin levels, troponin elevation occurred in 29 percent of the procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/3\">",
"       3",
"      </a>",
"      ]. Using the Joint",
"      <span class=\"nowrap\">",
"       ESC/ACCF/AHA/WHF",
"      </span>",
"      Task Force definition discussed above, PCI related MI occurred in about half. The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Elevated troponin was associated with a significantly increase risk of in-hospital major adverse cardiovascular events (the composite of all cause death, MI, repeat target vessel PCI, and coronary artery bypass grafting) (odds ratio [OR] 11.29, 95% CI 3.00-42.48) or death (OR 7.16, 95% CI 1.95-26.27).",
"     </li>",
"     <li>",
"      Troponin above the cut-off for MI was reported in a subset of patients (n = 2359) from four studies. In an unadjusted analysis, patients with PCI related MI had a significantly increased risk of death (OR 2.25, 95% CI 1.26-4.00) at 26-month follow-up. An increase of the troponin below the cut-off was not associated with major adverse cardiovascular events, but this finding may have been due to a relatively small sample size. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A review of 2352 patients who underwent PCI assessed the predictive value of baseline and postprocedural troponin (and CK-MB) concentrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/26\">",
"       26",
"      </a>",
"      ]. Baseline troponin elevations were present in 733 patients (31 percent) and were associated with worse short- and long-term outcomes. When these elevations were taken into account, neither postprocedural troponin (nor CK-MB) elevations added to the long-term prognostic significance. Postprocedural elevations or increases in the degree of elevation correlated only with in-hospital complications.",
"     </li>",
"     <li>",
"      A subsequent study from the Mayo Clinic, which evaluated only patients with normal pre-procedural levels of cTnT (and CK-MB), found that the 20 percent of patients with a postprocedural elevation of troponin had a significantly lower estimated three-year survival compared with those with normal troponin (86.9 versus 93.2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/18\">",
"       18",
"      </a>",
"      ]. The risk of in-hospital death was low irrespective of cTnT status.",
"     </li>",
"     <li>",
"      In a report of nearly 5000 patients undergoing elective coronary stent placement between 2004 and 2007, MI was defined as the peak value between 6 and 24 hours normalized to the local diagnostic level for MI and values greater than three times the upper limit of normal were classified as an MI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/43\">",
"       43",
"      </a>",
"      ]. After adjustment for differences in baseline characteristics, elevated troponin (and CK-MB) was significantly associated with one-year mortality (hazard ratio 1.35). The mortality hazard for troponin, however, was found only for much higher elevations. Troponin more than 20 times the diagnostic level demonstrated similar mortality risk as CK-MB more than three times the upper limit of normal. The mortality association may be overestimated by the absence of baseline troponin elevation as a co-variate in the multivariable analysis.",
"     </li>",
"     <li>",
"      A study of 2365 patients who underwent elective PCI for stable CAD assessed the predictive value of baseline and postprocedural troponin (and CK-MB) concentrations and provided a possible explanation for the discrepant findings in previous studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/26\">",
"       26",
"      </a>",
"      ]. Baseline troponin elevations had both short- and long-term prognostic significance. When these elevations were taken into account, post-procedural troponin (or CK-MB) elevations did not add to long-term prognostic significance. Post-procedural elevations or increases in the degree of elevation correlated only with in-hospital complications.",
"      <br/>",
"      <br/>",
"      This was the first study to use the baseline troponin measurement (as recommended in guidelines) in the analysis along with sensitive contemporary cut-off values, but has been confirmed by a larger analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/27\">",
"       27",
"      </a>",
"      ]. The marginal significance for in-hospital events was driven by non-cardiac events.",
"     </li>",
"     <li>",
"      In a study 5467 patients with non-ST elevation acute coronary syndromes enrolled in three randomized trials, there were 212 who experienced a procedure-related MI after five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/44\">",
"       44",
"      </a>",
"      ]. There was no difference in the cardiovascular death rate between those who had a procedure-related MI and those who did not (hazard ratio 0.90, 95% CI 0.47-1.71). This may reflect the fact that as assay sensitivity has increased, the baseline sample, even if the guideline-derived cut-off values are not used, still reduces any effect of post-PCI elevations.",
"     </li>",
"     <li>",
"      In a study of 13,608 patients with acute coronary syndrome undergoing PCI, among the 600 patients who experienced a type 4a (periprocedural) MI in the TRITON-TIMI 38 trial (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H22#H22\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Prasugrel'",
"      </a>",
"      ), 490 had elevated biomarkers before the procedure. Patients with NSTEMI (n = 335 with Type 4 MI) were enrolled and underwent PCI within 72 hours of qualifying symptoms of ACS, whereas patients with STEMI (n = 155 with Type 4 MI) could be enrolled up to two weeks after presentation. Then, if the baseline CK-MB was normal or lower than the original value, a threefold elevation &gt;upper limit of normal on two successive measurements or a fivefold elevation on a single sample post-PCI was associated with an increased risk of cardiovascular death at 180 days (3.2 versus 1.3 percent; adjusted hazard ratio 2.4, 95% CI 1.6-3.7). The rigorous approach taken in this study to discriminate periprocedural injury that was distinct from the qualifying ischemic syndrome may account for the ability to detect a significant risk relationship in this study. Application and refinement of this strategy in additional populations with ACS undergoing PCI will be important to understanding whether a similar approach will be valid with troponin-based definitions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of a new Q wave is associated with a worse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/5,45\">",
"     5,45",
"    </a>",
"    ]. In an analysis from the BARI trial, the increase in mortality with new Q waves after balloon angioplasty persisted at five years (18.1 versus 5.4 percent for no new ECG changes, adjusted relative risk 4.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/45\">",
"     45",
"    </a>",
"    ]. The mortality rate was intermediate with ST segment elevation or depression or T wave abnormalities &mdash; 8.5, 8.9, and 6 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88286209\">",
"    <span class=\"h2\">",
"     Prognosis summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Present guidelines favor troponin, as opposed to CK-MB, for both prognostic (and diagnostic) purposes. We believe obtaining a pre-PCI biomarker is a reasonable approach.",
"   </p>",
"   <p>",
"    Based on all available evidence, we conclude the following regarding the relationship between periprocedural elevations in biomarkers and prognosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An elevated biomarker (using the universal criteria for MI) before the procedure is associated with an adverse prognosis.&nbsp;",
"     </li>",
"     <li>",
"      The prognostic implication of an elevated biomarker after PCI cannot be known unless the baseline value is taken into account. In patients with an elevated baseline, prognosis is more directly linked to the baseline value than the post-procedural value.",
"      <br/>",
"      <br/>",
"      In patients with a normal baseline value, an elevated post-procedural troponin after an unsuccessful procedure or one with angiographic complications may be associated with an adverse short-term and long-term prognosis. After a seemingly uncomplicated procedure, there is even less certainty about the prognostic implications of a post-procedural rise in troponin. Many of these are not cardiovascular [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no studies that inform us as to the optimal management of patients with an elevated biomarker. The authors and reviewers of this topic generally agree with the approach laid out below, but believe that the care of each patient with a positive cTn should be individualized:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a baseline negative cardiac troponin and either a negative post-procedure value or no post-procedure value obtained (not indicated) are candidates for same-day discharge. The decision to do so should be based on co-morbidities, the risk for other acute complications such as bleeding, and local practice.",
"     </li>",
"     <li>",
"      For patients with an elevated cardiac troponin, either before or after the procedure, and especially if there are symptoms or complications of the procedure, keeping patient overnight is deemed to be prudent. The duration of hospitalization may be longer based on factors such as the clinical stability, indication for PCI, outcome during the case, biomarker",
"      <span class=\"nowrap\">",
"       peak/trajectory,",
"      </span>",
"      and the presence or absence of other acute processes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly associated patient-related risk factors are older age (in most studies &gt;65 years), the extent of coronary disease, the presence of pre-procedural acute coronary syndrome (including unstable angina) and pre-procedural elevation of cardiac markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/29\">",
"     29",
"    </a>",
"    ]. Other factors include a history of prior CABG, prior MI, low EF, diabetes, and smoking. A pre-procedural elevation of inflammatory markers such as high sensitivity C-reactive protein is associated with a two- to fourfold increase in periprocedural MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/46\">",
"     46",
"    </a>",
"    ]. PCI of degenerated saphenous vein grafts, multivessel interventions, and complex lesions, particularly those with evidence of thrombus, are also associated with an increased risk. Other procedural factors associated with postprocedural MI include the number and length of the stents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations of cardiac enzymes can be due to a number of factors including embolization of atheroma or thrombus, side branch occlusion, no reflow, epicardial or microvascular spasm, or stent thrombosis. With elevations of CK-MB &gt;5-8 x, ULN, distal vessel occlusion from a large embolus, acute stent thrombosis, or major side branch occlusion are usually responsible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smaller increases in cardiac enzymes are likely due to micro-embolization of thrombotic or atherosclerotic material. Evidence for micro-embolization comes from MRI studies that have shown small, irreversible myocardial injury in patients with elevated cardiac markers following PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/47,49\">",
"     47,49",
"    </a>",
"    ]. Since the size of the infarcts in this setting are small, these minor elevations have been felt to be a marker of more severe coronary atherosclerosis that is responsible for the poor prognosis in these patients. In addition, an enhanced inflammatory state (as evidenced by an elevated hsCRP) can predispose patients to thrombosis as well as vasospasm, and is felt to play a role as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism for a periprocedural ST elevation myocardial infarction (STEMI) is most commonly due to acute stent thrombosis or abrupt closure of the vessel, resulting in complete occlusion of the vessel. Rarely is it due to embolization of large thrombus or atheroma with distal vessel occlusion. Embolization is more common in degenerated saphenous vein graft interventions than in native vessel interventions.",
"   </p>",
"   <p>",
"    Distal embolization can contribute to the \"no-reflow\" phenomenon after PCI. No-reflow is thought to reflect microvascular dysfunction since there is evidence of myocardial ischemia and reduced antegrade coronary flow in the absence of epicardial stenosis or loss of a distal branch. In a report of patients undergoing PCI for a non-ST elevation acute coronary syndrome, those with a postprocedural troponin I elevation were significantly more likely to have reduced tissue-level perfusion than those without a troponin I elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link&amp;anchor=H4#H4\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'No-reflow phenomenon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between periprocedural elevation of serum biomarkers (NSTEMI) and distal microembolization was studied in 52 patients who underwent elective PCI for stable coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/51\">",
"     51",
"    </a>",
"    ]. Using intracoronary Doppler guidewire detection of emboli, the total number of microemboli during all phases of the intervention (device advancement over Doppler wire, predilatation, stent deployment and postdilatation) was significantly higher in patients with periprocedural NSTEMI compared to those without (27 versus 16). Microemboli were detected in all but one of the 52 patients and were seen most often during stent deployment.",
"   </p>",
"   <p>",
"    The relationships between the presence and effects of distal embolization and plaque composition were evaluated in a study of 44 patients with stable angina undergoing PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/52\">",
"     52",
"    </a>",
"    ]. Distal embolization was detected by the number of high-intensity transient signals (HITS) using a Doppler guidewire, plaque composition was evaluated using Virtual Histology intravascular ultrasound (Volcano Therapeutics, Inc) and the impact of distal embolization was assessed using measurement of coronary flow velocity reserve (CFVR). Patients in the highest tertile of HITS had a significantly larger necrotic core area compared with patients in lower tertiles. In addition, there was a small but significant negative correlation between HITS and CFVR after PCI.",
"   </p>",
"   <p>",
"    Similar findings have been noted in patients with STEMI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link&amp;anchor=H6#H6\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'Mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary mechanism of injury after PCI in saphenous vein grafts is distal embolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=see_link&amp;anchor=H25#H25\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Distal devices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple therapies for the prevention of periprocedural MI have been evaluated and include, among others, antiplatelet drugs, statins, ischemic preconditioning, adenosine, beta blockers and distal protection devices. These will be presented briefly here, but are discussed in detail separately with the exception of adenosine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of thienopyridines with or without glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors prior to stenting has been well studied. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=see_link\">",
"     \"Antithrombotic therapy for intracoronary stent implantation: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dual-antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a platelet P2Y12 receptor blocker can reduce complications, particularly periprocedural MI. Administration of the loading dose more than six hours before the procedure in the CREDO trial was associated with a significantly greater reduction in adverse events as compared to administration at the time of PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/55\">",
"     55",
"    </a>",
"    ]. Higher loading dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (600 mg versus 300 mg) is also associated with greater and more rapid inhibition of platelet function and reduced major cardiac events in patients undergoing PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of more potent P2Y12 receptor blockers, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    , has also been shown to reduce both short- and long-term adverse events and stent thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/14,57\">",
"     14,57",
"    </a>",
"    ]. In a post hoc analysis of the TRITON-TIMI 38 trial of 13,608 moderate- to high-risk ACS patients undergoing PCI, prasugrel significantly reduced the risk of periprocedural MI compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (4.9 versus 6.4 percent respectively, hazard ratio 0.76, 95% CI 0.66-0.88) during a mean follow-up of 14.5 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    also results in greater platelet inhibition and a reduction in MI and stent thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous platelet glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    antagonists have also been shown to reduce major adverse cardiac events in patients with NSTEMI and STEMI. However, studies have shown less benefit and increased bleeding when added to dual-antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend that they be considered in addition to aspirin and clopidogrel in NSTEMI patients who are high risk, especially when there are delays to angiography or recurrent ischemia. It is reasonable to omit GP",
"    <span class=\"nowrap\">",
"     IIb/IIa",
"    </span>",
"    agents when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    is used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/60\">",
"     60",
"    </a>",
"    ]. In addition, it is reasonable to use these agents in patients with a large thrombus burden, although there is little scientific evidence to support this approach. Routine upstream use prior to PCI is not currently recommended.",
"   </p>",
"   <p>",
"    The importance of adequate and rapid platelet inhibition before PCI has also been shown in registry studies. Up to 30 percent of patients have inadequate inhibition of platelet function to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (nonresponders). Using platelet function tests, such as the point of care VerifyNow TM test, lower rates of stent thrombosis, death, and MI have been demonstrated in patients who respond to dual therapy as compared to nonresponders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/61\">",
"     61",
"    </a>",
"    ]. Whether routine use of platelet function testing pre-PCI is of value in identifying and treating nonresponders is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=see_link\">",
"     \"Nonresponse and resistance to clopidogrel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept that pretreatment with statins might decrease the incidence of periprocedural MI stems in part from the observation that patients with acute coronary syndromes (in which there is local inflammation in one or more coronary arteries) benefit from the early use of statins. It is felt that PCI induces vascular injury with associated platelet aggregation and thrombosis, as well as local inflammation.",
"   </p>",
"   <p>",
"    Pre-procedural statin therapy has been shown to prevent periprocedural MI in multiple randomized trials in patients with both stable and unstable coronary artery disease. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=see_link&amp;anchor=H22#H22\">",
"     \"General principles of the use of intracoronary stents\", section on 'Statin therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33656?source=see_link\">",
"     \"Cholesterol lowering after an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Adenosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine induces dilatation of the microvasculature, modulates inflammation, and has other mechanisms of action that might be useful in the periprocedural period. It has been evaluated as an adjunctive therapy to reperfusion for ST elevation MI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/15/6394?source=see_link&amp;anchor=H16#H16\">",
"     \"Ischemic reperfusion injury of the heart\", section on 'Potential therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an open label study of the efficacy of adenosine in reducing periprocedural myonecrosis (defined as a CK-MB rise above the upper limit of normal), 62 patients scheduled to undergo non-urgent PCI of de novo coronary lesions were randomly assigned to pretreatment with either 50 &micro;g of intracoronary adenosine or no adenosine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/62\">",
"     62",
"    </a>",
"    ]. Intracoronary adenosine was associated with a significant reduction in myonecrosis (13 versus 39 percent, adjusted odds ratio 0.19, 95% CI 0.05-0.75) compared patients who received adenosine to those who did not. In addition, among patients with CK-MB elevations, the peak values were significantly lower in the adenosine group. Further studies are needed to confirm these results and to determine whether outcomes are improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ischemic preconditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of remote ischemic preconditioning to prevent biomarker elevation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39529?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical implications of ischemic preconditioning\", section on 'Percutaneous coronary intervention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Distal protection devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal embolic protection devices (DEPD) have been evaluated in two groups of patients undergoing PCI: patients with saphenous vein grafts and patients undergoing primary PCI.",
"   </p>",
"   <p>",
"    The use of DEPD has been shown to reduce complications and periprocedural MI in PCI of degenerated SVG by preventing distal embolization of atherosclerotic debris [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=see_link&amp;anchor=H25#H25\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Distal devices'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use in native coronary disease has been not been shown to be effective in reducing periprocedural MI.",
"   </p>",
"   <p>",
"    Randomized trials have not shown benefit of DEPD in the setting of primary PCI for ST elevation MI, even though the device removes a substantial amount of atheromatous debris. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link&amp;anchor=H10#H10\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'Distal embolic protection devices'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Thrombus aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of acute ST elevation MI, thrombectomy with aspiration of the occluding thrombus has been shown to reduce embolization, no reflow, and reduce infarct size and mortality in several randomized trials. A meta-analysis has confirmed these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/64\">",
"     64",
"    </a>",
"    ]. The protection and treatment of significant side branch disease can also reduce the chances of periprocedural MI. (\"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on Thrombectomy device).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of periprocedural MI depends upon the underlying cause. With acute stent thrombosis, immediate re-dilation of the occlusion with or without stenting is highly effective in reducing the size of the infarction. IVUS is helpful in ascertaining the cause of stent thrombosis in this setting, which may be the result of residual dissection or under deployment of the stent, among other causes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9623?source=see_link\">",
"     \"Coronary artery stent thrombosis: Clinical presentation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the case of distal embolization of a thrombus, mechanical disruption and fibrinolytic agents can improve flow. With athero-embolic material, this is not usually effective, and when the vessel is large enough, stenting across the debris is sometimes possible. If vasospasm or slow flow is evident, then use of intracoronary vasodilators, such as calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , or adenosine, can be helpful. Dissection and side branch occlusion can be treated with dilation and stenting of the occlusive lesions.",
"   </p>",
"   <p>",
"    In most cases, a periprocedural MI is silent and not detected during the procedure, but recognized afterwards if cardiac enzymes are routinely measured. Supportive measures alone are adequate for modest elevations (one to five-fold increases in CK-MB) when no clinical events have occurred. With minor elevation of cardiac enzymes and the absence of symptoms or complications, hospitalization does not need to be prolonged and no additional therapy is needed. For larger infarcts, such as Q wave infarcts and those with CK-MB or troponin elevation more than 5 x ULN, treatment should follow the guidelines for the management of spontaneous STEMI and NSTEMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR BIOMARKER MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest obtaining a baseline troponin in all patients undergoing PCI. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with suspected ischemia (prolonged chest pain, side branch occlusion, recurrent ischemia, flow limiting dissection, no-reflow, intracoronary thrombosis, or hemodynamic instability), troponin should be measured serially. We suggest obtaining two biomarkers after PCI (using the same biomarker as used before the procedure) separated three to six hours apart in patients when reinfarction is suspected.",
"    <br/>",
"    <br/>",
"    The 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Interventions guideline for PCI makes a strong recommendation for the measurement of cardiac biomarkers in patients with suspected ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39737/abstract/66\">",
"     66",
"    </a>",
"    ]. In addition, they state that routine measurement of cardiac biomarkers may be reasonable after PCI in all patients (a weak recommendation). We agree with these recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Percutaneous coronary intervention (PCI) is associated with a small, but significant, incidence of serious procedural complications such as death, stroke life threatening bleeding or large myocardial infarction (MI). Periprocedural myocardial necrosis, which can range from a minor elevation of cardiac biomarkers of necrosis to a large myocardial infarction (MI), is the most common complication. Approximately 20 percent of patients with normal pre-procedural CK-MB and cardiac troponin T (cTnT) values had an isolated postprocedural elevation in serum cardiac troponin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myocardial infarction associated with PCI is arbitrarily defined by elevation of cTn values &gt;5 x 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile upper reference limit (URL) in patients with normal baseline values (&le;99",
"      <sup>",
"       th",
"      </sup>",
"      percentile URL) or a rise of cTn values &gt;20 percent if the baseline values are elevated and are stable of falling. In addition, either (i) symptoms suggestive of myocardial ischemia, or (ii) new ischemic electrocardiographic changes or new left bundle branch block, or (iii) angiographic loss of patency of a major coronary artery or a side branch or persistent slow- or no-flow or embolization, or (iv) imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality are required. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An elevated cardiac biomarker before the procedure is associated with an adverse prognosis.&nbsp;Elevations after PCI may also carry a worse prognosis. Our approach to the use of biomarker testing before and after PCI is discussed above. (See",
"      <a class=\"local\" href=\"#H88286209\">",
"       'Prognosis summary'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple therapies for the prevention of periprocedural MI have been evaluated and include, among others, antiplatelet drugs, statins, ischemic preconditioning, adenosine, beta blockers and distal protection devices. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum troponin I or T should be measured in all patients with symptoms suggestive of an MI during or after PCI and in all patients with complicated procedures. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Recommendations for biomarker measurement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/1\">",
"      Venkitachalam L, Kip KE, Selzer F, et al. Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries. Circ Cardiovasc Interv 2009; 2:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/2\">",
"      Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation 2000; 102:2945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/3\">",
"      Testa L, Van Gaal WJ, Biondi Zoccai GG, et al. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM 2009; 102:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/4\">",
"      Weintraub WS, Mahoney EM, Ghazzal ZM, et al. Trends in outcome and costs of coronary intervention in the 1990s. Am J Cardiol 2001; 88:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/5\">",
"      Stone GW, Mehran R, Dangas G, et al. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients. Circulation 2001; 104:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/6\">",
"      Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998; 31:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/7\">",
"      Kugelmass AD, Cohen DJ, Moscucci M, et al. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. Am J Cardiol 1994; 74:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/8\">",
"      Mehran R, Dangas G, Mintz GS, et al. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions : intravascular ultrasound study of 2256 patients. Circulation 2000; 101:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/9\">",
"      Tardiff BE, Califf RM, Tcheng JE, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. J Am Coll Cardiol 1999; 33:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/10\">",
"      Brener SJ, Lytle BW, Schneider JP, et al. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002; 40:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/11\">",
"      Lindsey JB, Marso SP, Pencina M, et al. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. JACC Cardiovasc Interv 2009; 2:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/12\">",
"      Wang TY, Peterson ED, Dai D, et al. Patterns of cardiac marker surveillance after elective percutaneous coronary intervention and implications for the use of periprocedural myocardial infarction as a quality metric: a report from the National Cardiovascular Data Registry (NCDR). J Am Coll Cardiol 2008; 51:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/13\">",
"      Prasad A, Gersh BJ, Bertrand ME, et al. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 54:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/14\">",
"      Prasad A, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv 2008; 1:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/15\">",
"      Johansen O, Brekke M, Str&oslash;mme JH, et al. Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements. Eur Heart J 1998; 19:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/16\">",
"      Shyu KG, Kuan PL, Cheng JJ, Hung CR. Cardiac troponin T, creatine kinase, and its isoform release after successful percutaneous transluminal coronary angioplasty with or without stenting. Am Heart J 1998; 135:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/17\">",
"      Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 2000; 85:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/18\">",
"      Prasad A, Singh M, Lerman A, et al. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 2006; 48:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/19\">",
"      Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/20\">",
"      White HD. The prequel: defining prognostically important criteria in the periprocedural PCI troponin saga. Circ Cardiovasc Interv 2012; 5:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/21\">",
"      Jaffe AS, Apple FS, Lindahl B, et al. Why all the struggle about CK-MB and PCI? Eur Heart J 2012; 33:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/22\">",
"      Pierpont GL, McFalls EO. Interpreting troponin elevations: do we need multiple diagnoses? Eur Heart J 2009; 30:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/23\">",
"      Bonaca MP, Wiviott SD, Braunwald E, et al. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation 2012; 125:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/24\">",
"      Nienhuis MB, Ottervanger JP, Dikkeschei B, et al. Prognostic importance of troponin T and creatine kinase after elective angioplasty. Int J Cardiol 2007; 120:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/25\">",
"      Kleiman NS. Measuring troponin elevation after percutaneous coronary intervention: ready for prime time? J Am Coll Cardiol 2006; 48:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/26\">",
"      Miller WL, Garratt KN, Burritt MF, et al. Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. Eur Heart J 2006; 27:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/27\">",
"      Prasad A, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv 2008; 1:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/28\">",
"      Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012; 126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/29\">",
"      Herrmann J. Peri-procedural myocardial injury: 2005 update. Eur Heart J 2005; 26:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/30\">",
"      Blankenship JC, Haldis T, Feit F, et al. Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). Am J Cardiol 2006; 97:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/31\">",
"      Cavallini C, Savonitto S, Violini R, et al. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. Eur Heart J 2005; 26:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/32\">",
"      Akkerhuis KM, Alexander JH, Tardiff BE, et al. Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002; 105:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/33\">",
"      Saucedo JF, Mehran R, Dangas G, et al. Long-term clinical events following creatine kinase--myocardial band isoenzyme elevation after successful coronary stenting. J Am Coll Cardiol 2000; 35:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/34\">",
"      Ioannidis JP, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003; 42:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/35\">",
"      Jeremias A, Baim DS, Ho KK, et al. Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol 2004; 44:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/36\">",
"      Ellis SG, Chew D, Chan A, et al. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002; 106:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/37\">",
"      Pervaiz MH, Sood P, Sudhir K, et al. Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. Circ Cardiovasc Interv 2012; 5:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/38\">",
"      Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002; 39:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/39\">",
"      Kizer JR, Muttrej MR, Matthai WH, et al. Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. Eur Heart J 2003; 24:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/40\">",
"      Nageh T, Sherwood RA, Harris BM, et al. Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention. Int J Cardiol 2003; 92:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/41\">",
"      Kini AS, Lee P, Marmur JD, et al. Correlation of postpercutaneous coronary intervention creatine kinase-MB and troponin I elevation in predicting mid-term mortality. Am J Cardiol 2004; 93:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/42\">",
"      Wu AH, Boden WE, McKay RG. Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention. Am J Cardiol 2002; 89:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/43\">",
"      Novack V, Pencina M, Cohen DJ, et al. Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med 2012; 172:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/44\">",
"      Damman P, Wallentin L, Fox KA, et al. Long-term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 trials (FIR). Circulation 2012; 125:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/45\">",
"      Yokoyama Y, Chaitman BR, Hardison RM, et al. Association between new electrocardiographic abnormalities after coronary revascularization and five-year cardiac mortality in BARI randomized and registry patients. Am J Cardiol 2000; 86:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/46\">",
"      Goldberg A, Gruberg L, Roguin A, et al. Preprocedural C-reactive protein levels predict myocardial necrosis after successful coronary stenting in patients with stable angina. Am Heart J 2006; 151:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/47\">",
"      Porto I, Selvanayagam JB, Van Gaal WJ, et al. Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation 2006; 114:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/48\">",
"      Ross MJ, Herrmann HC, Moliterno DJ, et al. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. J Am Coll Cardiol 2003; 42:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/49\">",
"      Selvanayagam JB, Porto I, Channon K, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation 2005; 111:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/50\">",
"      Bolognese L, Ducci K, Angioli P, et al. Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2004; 110:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/51\">",
"      Bahrmann P, Werner GS, Heusch G, et al. Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris undergoing elective percutaneous coronary interventions. Circulation 2007; 115:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/52\">",
"      Kawamoto T, Okura H, Koyama Y, et al. The relationship between coronary plaque characteristics and small embolic particles during coronary stent implantation. J Am Coll Cardiol 2007; 50:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/53\">",
"      Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000; 101:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/54\">",
"      Webb JG, Carere RG, Virmani R, et al. Retrieval and analysis of particulate debris after saphenous vein graft intervention. J Am Coll Cardiol 1999; 34:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/55\">",
"      Steinhubl SR, Berger PB, Brennan DM, et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006; 47:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/56\">",
"      Lotrionte M, Biondi-Zoccai GG, Agostoni P, et al. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol 2007; 100:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/57\">",
"      Morrow DA, Wiviott SD, White HD, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation 2009; 119:2758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/58\">",
"      Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009; 53:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/59\">",
"      Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005; 46:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/60\">",
"      Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/61\">",
"      Price MJ. Monitoring platelet function to reduce the risk of ischemic and bleeding complications. Am J Cardiol 2009; 103:35A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/62\">",
"      Lee CH, Low A, Tai BC, et al. Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: a prospective randomized study. Eur Heart J 2007; 28:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/63\">",
"      Mauri L, Rogers C, Baim DS. Devices for distal protection during percutaneous coronary revascularization. Circulation 2006; 113:2651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/64\">",
"      Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur Heart J 2008; 29:2989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/65\">",
"      Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39737/abstract/66\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1574 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39737=[""].join("\n");
var outline_f38_51_39737=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      New Q waves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Evidence from elevated CK-MB studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Evidence from elevated troponin studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88286209\">",
"      Prognosis summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Adenosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Distal protection devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Thrombus aspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      RECOMMENDATIONS FOR BIOMARKER MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=related_link\">",
"      Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/37/41562?source=related_link\">",
"      Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/55/33656?source=related_link\">",
"      Cholesterol lowering after an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39529?source=related_link\">",
"      Clinical implications of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/25/9623?source=related_link\">",
"      Coronary artery stent thrombosis: Clinical presentation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/15/6394?source=related_link\">",
"      Ischemic reperfusion injury of the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=related_link\">",
"      Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_51_39738="Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas";
var content_f38_51_39738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Multimodality approaches to potentially resectable esophagogastric junction and gastric cardia adenocarcinomas",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/51/39738/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39738/contributors\">",
"     Ajlan Atasoy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39738/contributors\">",
"     Michael K Gibson, MD, PhD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39738/contributors\">",
"     Mark F Berry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/51/39738/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39738/contributors\">",
"     Joseph S Friedberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39738/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39738/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/51/39738/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39738/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/51/39738/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/51/39738/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18787235\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Esophageal and gastric cancers are significant worldwide health problems. They are often lethal diseases, with a case-fatality ratio of 84 percent (esophageal) and 75 percent (gastric), respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The esophagogastric junction (EGJ, also called the gastroesophageal junction or GEJ) and gastric cardia (",
"    <a class=\"graphic graphic_figure graphicRef79793 \" href=\"mobipreview.htm?4/45/4817\">",
"     figure 1",
"    </a>",
"    ), represent anatomical sites with a remarkably high and rapidly rising incidence of adenocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4661?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology of gastric cancer\", section on 'Change in histology pattern'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although surgery is the primary curative modality for EGJ cancers, long-term outcomes are not satisfactory with resection alone, even if microscopically complete (R0). This poor long-term outcome has prompted an evaluation of neoadjuvant (preoperative) and adjuvant (postoperative) combined modality therapy. The best form of multimodality therapy is not established.",
"   </p>",
"   <p>",
"    This topic will cover the definition and classification of EGJ tumors and provide an overview of the clinical trials that support the multimodality management of locally advanced but potentially resectable EGJ adenocarcinomas, focusing on considerations that influence the choice of the specific multimodality approach. Principles of surgical management for gastric tumors and thoracic esophageal tumors, treatment of locally advanced, unresectable esophageal cancers, adjuvant and neoadjuvant approaches to gastric cancers, and neoadjuvant and adjuvant approaches to tumors of the thoracic esophagus are covered elsewhere, as is management of dysplasia and early superficial cancer (including adenocarcinoma) arising in Barrett&rsquo;s esophagus.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33018?source=see_link\">",
"       \"Invasive gastric cancer: Surgery and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link\">",
"       \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=see_link\">",
"       \"Management of locally advanced unresectable esophageal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=see_link\">",
"       \"Adjuvant and neoadjuvant treatment of gastric cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link\">",
"       \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35802?source=see_link&amp;anchor=H14#H14\">",
"       \"Management of Barrett's esophagus\", section on 'Treatment of high-grade dysplasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20426?source=see_link\">",
"       \"Management of superficial esophageal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7933267\">",
"    <span class=\"h1\">",
"     DEFINITION AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of the EGJ is not standardized. It is defined differently by anatomists, physiologists, endoscopists, and pathologists:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomically, the EGJ is localized at the level of the angle of His, the point at which the tubular esophagus joins the cardia of the saccular stomach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Physiologists define the EGJ as the distal border of the lower esophageal sphincter, as determined by manometry.",
"     </li>",
"     <li>",
"      Endoscopically, the EGJ corresponds to the most proximal extent of the longitudinal gastric folds (",
"      <a class=\"graphic graphic_figure graphicRef76055 \" href=\"mobipreview.htm?10/63/11263\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. It is not the same as the squamocolumnar junction (SCJ), which forms a visible Z-line that marks the juxtaposition between the reddish columnar epithelium lining the gastric cardia and the pale glossy squamous epithelium lining the esophagus (",
"      <a class=\"graphic graphic_picture graphicRef69873 \" href=\"mobipreview.htm?43/32/44557\">",
"       picture 1",
"      </a>",
"      ). The SCJ is located approximately 3 to 10 mm proximal to the anatomically defined EGJ [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1161?source=see_link&amp;anchor=H4#H4\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus\", section on 'Diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pathologically, the EGJ is defined in an opened esophagogastrectomy specimen as the most proximal aspect of the gastric folds. The EGJ is located in the opened specimen by following the mucosa of the tubular esophagus to the top of the gastric folds. &nbsp;The EGJ location as defined by the pathologist is likely more precise than the location that is defined endoscopically, which can be limited both by respiratory and diaphragmatic motion during an endoscopic examination as well as by the presence of a hiatal hernia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of anatomic or endoscopic definitions such as &ldquo;end of the tubular esophagus&rdquo; or &ldquo;proximal limit of the gastric folds&rdquo; to define the EGJ should be avoided as these definitions place the EGJ at a point that can be over 2 cm proximal to the true physiologic EGJ, or 2 cm distal to it, within the cardia of the stomach.",
"   </p>",
"   <p>",
"    The gastric cardia is also imprecisely defined (",
"    <a class=\"graphic graphic_figure graphicRef79793 \" href=\"mobipreview.htm?4/45/4817\">",
"     figure 1",
"    </a>",
"    ). Anatomists describe the cardia as that zone of the stomach that is adjacent to the orifice of the tubular esophagus, but there is no anatomical landmark for the distal margin of the cardia. A definition of the cardia commonly used in Japan is the area within 2 cm above and below the EGJ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of a clear definition of the EGJ and gastric cardia has contributed to difficulties in classification of these tumors and has hampered definition of the optimal multimodality strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H497521\">",
"    <span class=\"h2\">",
"     AJCC classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNM staging system of the American Joint Committee on",
"    <span class=\"nowrap\">",
"     Cancer/International",
"    </span>",
"    Union Against Cancer",
"    <span class=\"nowrap\">",
"     (AJCC/UICC)",
"    </span>",
"    for esophageal and gastric cancer is used universally. In the latest (7",
"    <sup>",
"     th",
"    </sup>",
"    ) edition of the TNM staging manual, EGJ tumors are defined as those tumors arising at the EGJ or in the cardia of the stomach within 5 cm of the EGJ that extend into the EGJ or esophagus (",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/6\">",
"     6",
"    </a>",
"    ]. These tumors are staged as esophageal rather than gastric cancers. All other tumors with an epicenter in the stomach &gt;5 cm from the EGJ, or those within 5 cm or the EGJ without extension into the esophagus are staged as gastric cancers. In prior editions, tumors arising in the EGJ and gastric cardia that had minimal (2 cm or less) involvement of the esophagus were considered primary gastric cancers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'TNM staging criteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\", section on 'TNM staging criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12477151\">",
"    <span class=\"h2\">",
"     Siewert classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Siewert and Holsher published a topographic-anatomic subclassification scheme for EGJ adenocarcinomas in 1987 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/7\">",
"     7",
"    </a>",
"    ] that has been adopted by many clinicians; it was approved by the Seventh International Society for Diseases of the Esophagus in 1995 and by the Second International Gastric Cancer Congress in 1997 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/8\">",
"     8",
"    </a>",
"    ]. Within this classification, EGJ adenocarcinomas encompass all tumors with an epicenter within 5 cm proximal or distal to the anatomical Z-line (",
"    <a class=\"graphic graphic_figure graphicRef76055 \" href=\"mobipreview.htm?10/63/11263\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Siewert described three distinct categories of EGJ adenocarcinoma based upon anatomic location (",
"    <a class=\"graphic graphic_figure graphicRef64783 \" href=\"mobipreview.htm?32/24/33159\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Type I tumor",
"      </strong>",
"      (located between 5 cm and 1 cm proximal to the anatomical cardia (",
"      <a class=\"graphic graphic_figure graphicRef76055 \" href=\"mobipreview.htm?10/63/11263\">",
"       figure 2",
"      </a>",
"      )) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/9\">",
"       9",
"      </a>",
"      ] &ndash; Adenocarcinoma of the distal esophagus that usually arises from an area with specialized intestinal metaplasia of the esophagus (ie, Barrett&rsquo;s esophagus) and that may infiltrate the EGJ from above.",
"     </li>",
"     <li>",
"      <strong>",
"       Type II tumor",
"      </strong>",
"      (located between 1 cm proximal and 2 cm distal to the anatomical cardia) &ndash; True carcinoma of the cardia arising from the cardiac epithelium or short segments with intestinal metaplasia at the EGJ; this entity is also often referred to as &ldquo;junctional carcinoma&rdquo;.",
"     </li>",
"     <li>",
"      <strong>",
"       Type III tumor",
"      </strong>",
"      (located between 2 and 5 cm distal to the anatomical cardia) &ndash; Subcardial gastric carcinoma that infiltrates the EGJ and distal esophagus from below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most cases, classification is relatively straightforward based upon of the results of contrast radiography, endoscopy with orthograde and retroflexed view of the EGJ, computed tomography (CT) and sometimes, intraoperative appearance. However, in some cases, it may be difficult to distinguish the type for very locally advanced tumors that obliterate the EGJ and cross boundaries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'Preoperative staging evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27208?source=see_link&amp;anchor=H2#H2\">",
"     \"Endoscopic ultrasound in esophageal carcinoma\", section on 'Preoperative staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite some data suggesting that type",
"    <span class=\"nowrap\">",
"     II/III",
"    </span>",
"    tumors might be better classified using the gastric cancer TNM staging system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/10\">",
"     10",
"    </a>",
"    ], at present, all three Siewert types of EGJ adenocarcinoma are classified and staged as a single entity in the",
"    <span class=\"nowrap\">",
"     AJCC/UICC",
"    </span>",
"    cancer staging system for esophageal and EGJ cancers (",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/6\">",
"     6",
"    </a>",
"    ]. They all share a number of common morphologic features, and a similar prognosis, but there are differences with regard to epidemiology, etiology, distribution, and pattern of nodal metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Siewert type I tumors have epidemiologic and histologic characteristics that are similar to distal thoracic esophageal adenocarcinomas, including a strong male predominance, association with a history of reflux symptoms, and a predominance of intestinal-type histology, having arisen from Barrett&rsquo;s intestinal metaplasia secondary to gastroesophageal reflux [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8391?source=see_link\">",
"       \"Pathogenesis of Barrett's esophagus and its malignant transformation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1161?source=see_link&amp;anchor=H5#H5\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus\", section on 'Intestinal metaplasia at the GEJ and in the gastric cardia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=see_link&amp;anchor=H2#H2\">",
"       \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\", section on 'Epidemiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=see_link&amp;anchor=H2100395#H2100395\">",
"       \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\", section on 'Etiologic factors'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In contrast, type III tumors resemble distal (non-cardia) gastric cancers, with a similar proportion of diffuse and intestinal histologic types and no association with reflux. They arise from the gastric mucosa, and their origin might be associated with Helicobacter pylori (H pylori) and atrophic gastritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/16\">",
"       16",
"      </a>",
"      ]. Type III (and II) tumors have a less strong male predominance than do type I cancers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4661?source=see_link\">",
"       \"Epidemiology of gastric cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/618?source=see_link\">",
"       \"Risk factors for gastric cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There is increasing evidence to suggest that Siewert type II tumors have two distinct etiologies, some being esophageal adenocarcinomas probably arising from short or ultrashort Barrett&rsquo;s esophagus, and others gastric adenocarcinomas caused by H pylori infection and atrophic gastritis (as with type III tumors) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/17-19\">",
"       17-19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For the purpose of multimodality treatment, EGJ tumors are all treated similarly, although the operative approach differs, partly because of the differing pattern of nodal spread (",
"      <a class=\"graphic graphic_figure graphicRef64783 \" href=\"mobipreview.htm?32/24/33159\">",
"       figure 3",
"      </a>",
"      ). In general, type I cancers more frequently involve lymph nodes in the upper mediastinum (tracheal bifurcation and above) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/20\">",
"       20",
"      </a>",
"      ]. Patients with type I tumors are not appropriate candidates for a purely transabdominal approach to resection. The standard surgical approach is a transthoracic en bloc esophagectomy combined with resection of the upper part of the stomach and two-field lymphadenectomy.",
"      <br/>",
"      <br/>",
"      On the other hand, for type II and III carcinomas, nodal metastases are more frequently found in the lower mediastinum and around the celiac trunk. The standard surgical approach is a transhiatally extended total gastrectomy with distal esophageal resection and systemic lymphadenectomy of nodes that drain the stomach. (See",
"      <a class=\"local\" href=\"#H944579\">",
"       'Surgical management'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link&amp;anchor=H7377444#H7377444\">",
"       \"Surgical oncologic principles for management of resectable esophageal cancer\", section on 'Esophagogastric junction cancer resection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H944333\">",
"    <span class=\"h1\">",
"     PRETREATMENT STAGING EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of adenocarcinoma of the EGJ and gastric cardia is usually established by an endoscopic biopsy. &nbsp;In addition to achieving a biopsy, the endoscopist should document tumor location relative to both the teeth and the EGJ, tumor length, extent of circumferential involvement, degree of obstruction, and any evidence of Barrett&rsquo;s esophagus to assist with treatment planning. The specific Siewert type (I, II, or III) can often be defined endoscopically, although endoscopic localization of the EGJ can be hindered by the presence of a hiatal hernia and by respiratory and diaphragmatic motion during the evaluation. (See",
"    <a class=\"local\" href=\"#H12477151\">",
"     'Siewert classification'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7933267\">",
"     'Definition and classification'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'Biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link\">",
"     \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once a diagnosis is established, a staging evaluation is undertaken to ascertain disease extent and location. At the completion of the staging evaluation, information on tumor location, extent, and potential resectability enables the choice of the most appropriate multimodality treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'Overview of the preoperative staging evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Staging usually begins with a CT scan to evaluate for the presence of metastatic disease. Patients without evidence of metastatic disease undergo endoscopic ultrasonography (EUS), which uses a high frequency ultrasound transducer to provide detailed images of esophageal masses and their relationship with the five-layered structure of the esophageal wall. EUS is the most accurate technique for locoregional staging of invasive esophageal cancer (including tumors arising at the EGJ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/21\">",
"     21",
"    </a>",
"    ]), with an overall accuracy for tumor (T) and node (N) staging of 80 to 90 percent. EUS allows assessment of both perigastric and mediastinal lymph nodes, which can potentially be sampled during the evaluation with a fine needle aspiration biopsy if the result would impact treatment decisions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27208?source=see_link&amp;anchor=H2#H2\">",
"     \"Endoscopic ultrasound in esophageal carcinoma\", section on 'Preoperative staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5353119\">",
"    <span class=\"h2\">",
"     PET and PET-CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;PET and integrated PET-CT scans are useful to detect metastatic disease in patients who are otherwise believed to be surgical candidates after routine staging with conventional contrast-enhanced helical CT. Suspicious PET findings should be confirmed with biopsy before excluding a patient from surgical consideration given the high rate of false positive findings.",
"   </p>",
"   <p>",
"    Integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging is increasingly favored over PET alone due to better spatial resolution. It involves performance of both PET and CT sequentially during a single visit on a hybrid",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanner. However, the CT component of integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging is performed in most institutions without the use of IV contrast, which compromises the detection of small metastases both within and outside of the liver. In the absence of IV contrast, an integrated PET-CT cannot substitute for a dedicated IV contrast-enhanced CT. At some institutions,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is carried out with IV contrast, but this practice is not widespread. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'Evaluation for distant metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another area in which integrated",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    may be of clinical utility is in restaging after initial induction therapy. (See",
"    <a class=\"local\" href=\"#H5353223\">",
"     'Use of PET and PET-CT during treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Consensus-based guidelines for staging, such as those published by the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    , do not recommend routine pretreatment brain imaging for patients with esophageal or EGJ cancers. Brain metastases have been considered uncommon in patients with esophageal cancer (published incidence &lt;5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]). &nbsp;However, in more contemporary esophageal cancer cohorts with a higher percentage of adenocarcinoma, the incidence of brain metastases may be higher (13 percent in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/24\">",
"     24",
"    </a>",
"    ]). Despite these data, however, routine brain imaging is not considered cost-effective or necessary as part of the routine staging evaluation unless symptoms or signs raise suspicion for brain metastases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3443822\">",
"    <span class=\"h2\">",
"     Diagnostic laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraperitoneal metastases are common with EGJ adenocarcinomas and notoriously difficult to diagnose noninvasively. The role of staging laparoscopy is controversial, and there is no consensus on this issue from expert groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consensus-based guidelines from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      , consider diagnostic laparoscopy to be \"optional\" for patients with EGJ tumors and no evidence of metastatic disease.",
"     </li>",
"     <li>",
"      Guidelines from the EORTC advocate diagnostic laparoscopy for all patients with locally advanced",
"      <span class=\"nowrap\">",
"       (T3/4)",
"      </span>",
"      adenocarcinomas of the EGJ infiltrating the gastric cardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) generally recommends diagnostic laparoscopy for all patients with esophageal and EGJ cancer who are considered candidates for curative resection based on non-invasive staging studies (a grade B recommendation) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We routinely perform diagnostic laparoscopy for patients who appear to have potentially clinical T3 or T4 (",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"     table 1",
"    </a>",
"    ) or Siewert II-III adenocarcinomas of the EGJ, or if there is suspicion for intraperitoneal metastatic disease that cannot otherwise be confirmed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/27\">",
"     27",
"    </a>",
"    ]. The procedure involves full inspection of the peritoneal cavity to evaluate for peritoneal and liver metastases. The EGJ area can be visualized for tumor extension, and biopsies of lymph nodes in the gastrohepatic ligament and the celiac axis can be undertaken if necessary. Lavage may also be sent for peritoneal cytology. Opinion differs as to the optimal way to manage such patients. At some institutions, patients without overt intraperitoneal metastases but who have positive peritoneal washings are referred for neoadjuvant therapy and then restaged to determine whether they converted to negative cytology and are candidates for potentially curative surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33018?source=see_link&amp;anchor=H4#H4\">",
"     \"Invasive gastric cancer: Surgery and prognosis\", section on 'Staging laparoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal timing of diagnostic laparoscopy is dependent on the specific clinical situation. If the patient requires a feeding J-tube or a port for chemotherapy prior to any treatment, then diagnostic laparoscopy can be performed at that time. If the treatment plan based on staging studies is to perform surgical resection prior to any other neoadjuvant therapy, then starting with laparoscopy at the time the resection is planned is a reasonable approach so that the patient does not require a separate procedure and additional episode of general anesthesia. Biopsies can be performed and a more invasive surgical approach can be avoided if unexpected findings are encountered, which may allow the patient to proceed to other therapy more quickly than if laparotomy had been performed. &nbsp;Somewhat similarly, if the patient is planned to get a course of neoadjuvant chemoradiation that would not be adjusted even if surgical resection were not planned, then the laparoscopy can again be planned for the time the patient is taken for their resection. Other scenarios can be judged on a case by case basis, though in general diagnostic laparoscopy would be recommended prior to treatment if staging studies are suspicious for peritoneal disease and otherwise at the time of the planned resection as above. If a patient has had a prior diagnostic laparoscopy, repeat diagnostic laparoscopy at the time of planned resection is generally not required if the patient does not have any new suspicious radiologic findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'Laparoscopy and thoracoscopy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7933267\">",
"     'Definition and classification'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link\">",
"     \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3444420\">",
"    <span class=\"h2\">",
"     Indicators of unresectability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of peritoneal, lung, bone, adrenal, brain, or liver metastases, or extraregional lymph node spread (eg, paraaortic or mesenteric lymphadenopathy) precludes an attempt at resection. Celiac nodal metastases and",
"    <span class=\"nowrap\">",
"     mediastinal/supraclavicular",
"    </span>",
"    nodes are scored as regional nodal disease in the new 2010 edition of the TNM staging system, regardless of the primary tumor location; it is the number of involved nodes rather than location that determines the N stage (",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'Regional lymph nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    T1 to T3 lesions are considered potentially resectable. T4 lesions that involve the pericardium, pleura, or diaphragm are potentially resectable, while involvement of other organs precludes resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7932647\">",
"    <span class=\"h1\">",
"     EVOLUTION OF TREATMENT PHILOSOPHY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3446455\">",
"    <span class=\"h2\">",
"     Epidemiologic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geographic variation and changes in the epidemiology of esophageal cancer, especially in Western (non-Asian) countries, are striking over the last 20 to 30 years. Worldwide, squamous cell cancer is still the most common subtype of esophageal cancer but adenocarcinoma is now the most prevalent in the West.",
"   </p>",
"   <p>",
"    In Western countries, primary tumor location has changed in tandem with histology. Distal esophagus, EGJ, and proximal gastric cancer are now the dominant sites of disease in the West [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/28\">",
"     28",
"    </a>",
"    ]. In particular, the incidence of adenocarcinoma of the EGJ has been increasing at 5 to 10 percent annually since the mid 1970s and is now the most rapidly increasing cancer in many Western countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. In the United States, there has been a five- to sixfold increase in the incidence of cancers arising in the gastric cardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/29,32\">",
"     29,32",
"    </a>",
"    ]. Increases in annual rates for adenocarcinoma of gastric cardia have been observed in both white males (from 2.1 to 3.3 per 100,000 population) and black males (from 1.0 to 1.9 per 100,000) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4661?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology of gastric cancer\", section on 'Change in histology pattern'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These epidemiologic shifts have served to focus attention on adenocarcinomas of the distal esophagus, EGJ and proximal stomach as a distinct entity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3446618\">",
"    <span class=\"h2\">",
"     Multimodality therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;EGJ adenocarcinomas anatomically straddle the distal esophagus and proximal stomach, and their management has thus reflected approaches for both esophageal and gastric adenocarcinomas. (See",
"    <a class=\"local\" href=\"#H12477151\">",
"     'Siewert classification'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link&amp;anchor=H7377444#H7377444\">",
"     \"Surgical oncologic principles for management of resectable esophageal cancer\", section on 'Esophagogastric junction cancer resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complete surgical resection is a prerequisite for cure. However, the poor results with surgery alone in both of these situations have prompted an evaluation of multimodality (ie neoadjuvant [preoperative] and adjuvant [postoperative]) strategies aimed at improving survival in patients with apparently localized disease.",
"   </p>",
"   <p>",
"    Defining optimal multimodality treatment for EGJ adenocarcinomas has been difficult for a number of reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/33\">",
"     33",
"    </a>",
"    ], one of which is the lack of trials that focus on the EGJ. For example, only one trial, the German POET trial of neoadjuvant chemoradiotherapy versus induction chemotherapy alone, treated EGJ tumors as a separate entity. (See",
"    <a class=\"local\" href=\"#H3447368\">",
"     'German POET trial'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    Most of the data that informs the multimodality treatment of EGJ adenocarcinoma is derived from trials that involved predominantly gastric or esophageal cancers. Within the trials designed primarily for gastric cancer (which will be considered &ldquo;lower tract trials&rdquo; for the purpose of this review), patients with EGJ tumors have accounted for only about 20 percent of all enrollees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. There are epidemiologic and pathobiologic differences between EGJ and non-cardia gastric adenocarcinomas that raise concern as to whether results from predominantly gastric cancer trials can be extrapolated to EGJ tumors. Gastric tumors are associated with H pylori infection, chronic gastritis and low acid production, while EGJ tumors tend to be associated with obesity, high acid production, gastroesophageal reflux disease, and are inversely associated with H pylori [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/618?source=see_link\">",
"     \"Risk factors for gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, the clinical characteristics, biologic behavior, and survival after esophagectomy for EGJ adenocarcinomas seem to be similar to those of adenocarcinomas arising in the distal esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/37\">",
"     37",
"    </a>",
"    ] and gastric cardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/38\">",
"     38",
"    </a>",
"    ]. Trials of multimodality therapy for esophageal cancer (which will be designated &ldquo;upper tract trials&rdquo; for this review) have included a larger percentage of patients with distal esophageal and EGJ adenocarcinomas, although the majority of distal esophageal tumors have been squamous cell cancers (SCCs). While most clinical studies have not stratified outcomes according to histology, an increasing amount of evidence supports the view that SCCs differ from adenocarcinomas in terms of pathogenesis, epidemiology, tumor biology, and prognosis. Esophageal SCCs are strongly associated with alcohol and tobacco use while adenocarcinomas are associated with gastroesophageal reflux and high body mass. (See",
"    <a class=\"local\" href=\"#H3446455\">",
"     'Epidemiologic changes'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In acknowledgement of these differences, the most recent 2010 TNM staging system provides separate stage groupings (but similar definitions for T, N, M and grade [G] categories) for SCCs and adenocarcinomas of the esophagus and EGJ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/39\">",
"     39",
"    </a>",
"    ]. However, it remains unclear as to whether or how histology should dictate the therapeutic approach. Future studies in esophageal cancer should analyze and report separately the results of therapeutic strategies according to histology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link&amp;anchor=H2#H2\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Squamous cell versus adenocarcinoma'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Significant progress has been made in the past two decades in the multimodality management of locally advanced nonmetastatic gastric and esophageal cancer. In particular, three major trials that included patients with EGJ tumors have influenced multimodality management:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      US Intergroup 0116 demonstrated the advantage of postoperative chemoradiotherapy in patients with resected gastric and EGJ adenocarcinomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=see_link&amp;anchor=H3#H3\">",
"       \"Adjuvant and neoadjuvant treatment of gastric cancer\", section on 'Intergroup 0116'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The European MAGIC trial demonstrated the survival benefit of perioperative chemotherapy with ECF (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      ) in patients with distal esophageal, EGJ and gastric adenocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/34\">",
"       34",
"      </a>",
"      ]. The success of this trial raised questions as to whether radiotherapy was a necessary component of treatment for gastric and EGJ cancers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=see_link&amp;anchor=H8#H8\">",
"       \"Adjuvant and neoadjuvant treatment of gastric cancer\", section on 'MAGIC trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most recently, the German POET trial demonstrated modest, clinically relevant but not statistically significant benefits of neoadjuvant chemotherapy plus chemoradiotherapy versus induction chemotherapy alone in patients with EGJ adenocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3447368\">",
"       'German POET trial'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While randomized trials have not consistently shown a survival benefit for neoadjuvant chemotherapy or chemoradiotherapy over surgery alone, multiple meta-analyses have concluded that neoadjuvant therapy is superior to surgery alone in the treatment of esophageal cancer; none of these have distinguished EGJ adenocarcinomas from other esophageal cancers. These data are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link&amp;anchor=H14#H14\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Meta-analyses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13892529\">",
"    <span class=\"h3\">",
"     Necessity for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although randomized trials comparing surgical versus non-surgical treatment have never been performed, resection is generally considered integral to achieving cure in patients with esophageal and EGJ cancers. In a study from the linked Surveillance, Epidemiology, and End-Results (SEER)-Medicare database, five-year survival rates for patients with stages I-III esophageal cancer treated with and without surgery were 28 and 10 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/41\">",
"     41",
"    </a>",
"    ]. However, these data must be interpreted cautiously. The longer survival in the surgically treated patients could represent selection bias in that younger and healthier patients may have been selected to undergo more aggressive initial treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link\">",
"     \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the data on definitive chemoradiotherapy for esophageal cancer are in patients with squamous cell cancer; there are few data for adenocarcinoma, and pathologic complete response rates after chemoradiotherapy are lower for adenocarcinoma as compared to squamous cell cancer. Thus, for patients with adenocarcinoma of the EGJ, we reserve definitive chemoradiotherapy for those patients who refuse surgery, or are not surgical candidates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link&amp;anchor=H18#H18\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Necessity for surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13892643\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined modality therapy has become a standard approach for patients with T2-3,N0 stage I, and all patients with stages IIA, IIB, and III esophageal, EGJ and gastric cardia cancers (",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"     table 1",
"    </a>",
"    ). However, the best form of multimodality therapy is not established. &nbsp;Patients with EGJ adenocarcinoma are treated variably with neoadjuvant chemotherapy alone, preoperative chemoradiotherapy, or postoperative chemoradiotherapy, depending mostly on the biases of the treating team of doctors, and in some cases, whether the patient is initially seen by a surgeon or a",
"    <span class=\"nowrap\">",
"     medical/radiation",
"    </span>",
"    oncologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H944579\">",
"    <span class=\"h1\">",
"     SURGICAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12480650\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The operative procedures for the surgical management of EGJ cancer are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link&amp;anchor=H7377444#H7377444\">",
"     \"Surgical oncologic principles for management of resectable esophageal cancer\", section on 'Esophagogastric junction cancer resection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18787330\">",
"    <span class=\"h2\">",
"     Outcomes with surgery alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete resection is a prerequisite for cure of EGJ adenocarcinoma, but long-term outcomes are not satisfactory with resection alone, even if it is microscopically complete (R0):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data from several contemporary surgical series of esophageal and EGJ cancer report five-year survival rates of 15 to 20 percent for patients treated with esophagectomy alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/42-44\">",
"       42-44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an analysis of 4627 patients with esophageal cancer (60 percent adenocarcinoma) who were treated with surgery alone without adjuvant or neoadjuvant therapy, five-year survival rates were &lt;50 percent for all disease stages except stage I (T1N0 according to the 6",
"      <sup>",
"       th",
"      </sup>",
"      edition of the AJCC TNM staging system), and they were 15 percent for any patient with node-positive disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Dutch and Japanese surgical trials reported above, in which all patients underwent surgery alone, five-year survival rates were 34 and 52 percent, respectively. However, these high numbers likely reflect patient selection more than effect on outcomes. In both trials, there were a substantial number of patients with T1 or T2 tumors (25 to 30 percent in the Dutch trial, and 35 to 40 percent in the Japanese trial). (See",
"      <a class=\"local\" href=\"#H944579\">",
"       'Surgical management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link\">",
"       \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these data, combined modality therapy has become a standard approach for locoregionally advanced but potentially resectable stage II and III esophageal and EGJ cancers (",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"     table 1",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12480581\">",
"    <span class=\"h1\">",
"     MULTIMODALITY APPROACHES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18787392\">",
"    <span class=\"h2\">",
"     Perioperative chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pre- and postoperative systemic chemotherapy has been extensively studied as a strategy to both improve chances of R0 (microscopically complete) resection and treat early micrometastatic disease. In general, trials focused on two groups; distal",
"    <span class=\"nowrap\">",
"     esophagus/EGJ",
"    </span>",
"    (upper tract) and",
"    <span class=\"nowrap\">",
"     EGJ/true",
"    </span>",
"    gastric (lower tract). In each case, the EGJ subtype usually made up the minority of tumors, and most upper tract studies included SCC. Many of these trials suffer from misclassification of anatomic site of involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H944964\">",
"    <span class=\"h3\">",
"     Upper GI tract trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two trials of preoperative chemotherapy in patients with esophageal cancer included those with EGJ primary sites. One trial (the Medical Research Council [MRC] OE2 trial of surgery with or without preoperative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    [FU]) demonstrated a survival benefit for this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/46,47\">",
"     46,47",
"    </a>",
"    ], while the second, US Intergroup trial 0113 (which used the same basic design) did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/42\">",
"     42",
"    </a>",
"    ]. These trials are all discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link&amp;anchor=H19#H19\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H945003\">",
"    <span class=\"h3\">",
"     Lower GI tract trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three relevant trials of perioperative chemotherapy versus surgery alone in patients with gastric cancer that included individuals with EGJ tumors; two show a survival benefit for this approach (the MAGIC and French",
"    <span class=\"nowrap\">",
"     FNLCC/FFCD",
"    </span>",
"    trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/34,48\">",
"     34,48",
"    </a>",
"    ]), while a third (EORTC trial 40954) does not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=see_link&amp;anchor=H4#H4\">",
"     \"Adjuvant and neoadjuvant treatment of gastric cancer\", section on 'Neoadjuvant/perioperative chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18787448\">",
"    <span class=\"h4\">",
"     MAGIC trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the largest and most influential of these trials, the MRC MAGIC trial, 503 patients with potentially resectable gastric (74 percent), lower esophageal (15 percent), or EGJ adenocarcinomas (11 percent) were randomly assigned to surgery alone or surgery plus perioperative chemotherapy (three preoperative and three postoperative cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and infusional 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    [ECF] (",
"    <a class=\"graphic graphic_table graphicRef62502 \" href=\"mobipreview.htm?35/44/36558\">",
"     table 2",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/34\">",
"     34",
"    </a>",
"    ]. This is the only trial that required postoperative chemotherapy.",
"   </p>",
"   <p>",
"    A higher proportion of chemotherapy-treated patients with gastric cancer who underwent radical surgery had a potentially curative procedure (79 versus 70 percent), and significantly more had",
"    <span class=\"nowrap\">",
"     T1/2",
"    </span>",
"    tumors (52 versus 37 percent) and",
"    <span class=\"nowrap\">",
"     N0/N1",
"    </span>",
"    disease (84 versus 71 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/50\">",
"     50",
"    </a>",
"    ]. Chemotherapy was well tolerated overall; excluding patients with neutropenia (23 percent), fewer than 12 percent of all patients had serious (grade 3 or 4) toxic effects. Despite this, only 104 (42 percent) were able to complete protocol treatment, including surgery and all three cycles of the postoperative chemotherapy. These data underscore one of the major problems with the perioperative approach, which is the difficulty in administering full number of postoperative chemotherapy cycles.",
"   </p>",
"   <p>",
"    Nevertheless, with median four-year follow-up, progression-free survival was significantly worse in the surgery alone group as was overall survival (HR 0.75). The 25 percent reduction in the risk of death favoring chemotherapy translated into an improvement in five-year survival from 23 to 36 percent. Local failure occurred in 14 percent of the chemotherapy-treated patients compared to 21 percent of those undergoing surgery alone, while distant metastases developed in 24 and 37 percent of patients, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18787463\">",
"    <span class=\"h4\">",
"     French FNLCC/FFCD trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar benefit for neoadjuvant chemotherapy was noted in a French multicenter trial in which 224 patients with potentially resectable stage II or greater adenocarcinoma of the stomach (n = 55), EGJ (n = 144) or distal esophagus (n = 25)",
"    <strong>",
"    </strong>",
"    were randomly assigned to two to three cycles of preoperative chemotherapy (infusional FU 800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day for five consecutive days, once every 28 days plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) or surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/48\">",
"     48",
"    </a>",
"    ]. Three to four cycles of postoperative chemotherapy were administered to patients who tolerated the preoperative regimen and who had no evidence of progressive disease (approximately 50 percent of all patients).",
"   </p>",
"   <p>",
"    Patients undergoing perioperative chemotherapy were significantly more likely to undergo R0 resection (84 versus 73 percent), and there was a statistically insignificant trend toward fewer",
"    <span class=\"nowrap\">",
"     pT3/4",
"    </span>",
"    lesions (58 versus 68 percent) and fewer node-positive tumors (67 versus 80 percent). At a median 5.7-year follow-up, neoadjuvant chemotherapy was associated with a significant 35 percent reduction in the risk of disease recurrence, and survival was also significantly better in the chemotherapy group (HR for death 0.69, 95 percent CI: 0.50-0.95, which translated into a five-year survival 38 versus 24 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3089293\">",
"    <span class=\"h3\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A survival benefit for neoadjuvant chemotherapy was shown in a year 2011 meta-analysis that included 9 randomized comparisons of neoadjuvant chemotherapy versus surgery alone for esophageal or EGJ cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/51\">",
"     51",
"    </a>",
"    ]. The hazard ratio (HR) for all-cause mortality for neoadjuvant chemotherapy was 0.87 (95% CI 0.70-0.88), and this translated into an absolute survival benefit at two years of 5.1 percent; the number needed to treat to prevent one death was 19. The potential benefit of neoadjuvant therapy was not offset by a higher perioperative mortality. In subgroup analysis, for those studies where histology data were available, the HR for all cause mortality for adenocarcinomas was 0.75 (95% CI 0.59-0.95) in favor of chemotherapy. These data support a significant survival benefit for neoadjuvant chemotherapy over surgery alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18787489\">",
"    <span class=\"h2\">",
"     Neoadjuvant concurrent chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the goal of increasing both local control (higher pathologic complete response) and systemic control, preoperative and postoperative concurrent chemoradiotherapy have both been studied in randomized trials, many of which included patients with EGJ adenocarcinoma.",
"   </p>",
"   <p>",
"    All of the trials studying neoadjuvant chemoradiotherapy are &ldquo;upper GI tract&rdquo; trials. Of the five completed randomized trials comparing preoperative concurrent chemoradiotherapy versus surgery alone for upper GI tract cancers that included patients with EGJ tumors, only two (the Irish trial, and the Dutch CROSS trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]) show a statistically significant survival benefit for chemoradiotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link&amp;anchor=H12#H12\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Concurrent chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5373124\">",
"    <span class=\"h3\">",
"     CROSS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The larger of the two trials, the Dutch CROSS trial, randomly assigned 363 patients with potentially resectable esophageal or EGJ cancer (86 SCC, 273 adenocarcinoma, four other; majority distal esophageal, 11 percent EGJ) to preoperative chemoradiotherapy versus surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/53\">",
"     53",
"    </a>",
"    ]. Preoperative treatment consisted of weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    (area under the curve of concentration X time [AUC] of 2) plus concurrent RT (41.4 Gy over five weeks).",
"   </p>",
"   <p>",
"    In a preliminary report presented at the 2010 ASCO meeting, preoperative chemoradiotherapy was well tolerated; the only grade 3 or worse toxicity was leukopenia (7 percent). The complete (R0) resection rate was higher with chemoradiotherapy (92 versus 65 percent), and 33 percent of those treated with chemoradiotherapy had a pathologic complete response. At a median follow-up of 32 months, overall survival was significantly better with preoperative chemoradiotherapy (three-year survival rate 59 versus 48 percent).",
"   </p>",
"   <p>",
"    In contrast, three other trials have not shown a significant survival advantage for the neoadjuvant chemoradiotherapy approach as compared to surgery alone, two of which were likely underpowered (the Michigan trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/54\">",
"     54",
"    </a>",
"    ], and CALGB 9781 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/55\">",
"     55",
"    </a>",
"    ]). The third trial, FFCD 9901, was limited to patients with stage I and II disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link&amp;anchor=H12#H12\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Concurrent chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3089538\">",
"    <span class=\"h3\">",
"     CALGB 9781",
"    </span>",
"    &nbsp;&mdash;&nbsp;In CALGB 9781, for example, patients were randomly assigned to surgery with or without preoperative chemoradiotherapy (50.4 Gy external beam RT in 1.8 daily fractions, five days per week, and concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 29) and infusional FU (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day by continuous infusion for 96 hours, days 1 through 4 and 29 through 32, after cisplatin). Due to poor accrual, the study was closed prematurely with only 56 patients enrolled (42 adenocarcinoma); the number of patients with primary EGJ tumors was not reported.",
"   </p>",
"   <p>",
"    A pathologic complete response was achieved in 10 of 25 assessable patients in the trimodality arm (40 percent), and neither perioperative morbidity nor mortality was increased compared to surgery alone. Although the difference in five-year survival was potentially clinically meaningful (39 versus 16 percent) in favor of trimodality therapy, the difference was not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12481359\">",
"    <span class=\"h3\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several meta-analyses support a survival benefit for neoadjuvant concurrent chemoradiotherapy compared to surgery alone for esophageal and EGJ cancer. The most recent and largest of these included 12 randomized comparisons of neoadjuvant chemoradiotherapy (either concurrent or sequential) versus surgery alone for esophageal or EGJ cancer, and included the FFCD 9901, CALGB 9781, and CROSS trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/51\">",
"     51",
"    </a>",
"    ]. The HR for all-cause mortality for neoadjuvant chemoradiotherapy was 0.78 (95% CI 0.70-0.88), and this translated into an absolute survival benefit of 8.7 percent at two years; the number needed to treat to prevent one death was 11. The benefit was similar across histologic subtypes; for adenocarcinomas, the HR for all cause mortality was 0.75, 95% CI 0.59-0.95, favoring neoadjuvant concurrent chemoradiotherapy. The potential benefit of neoadjuvant therapy was not offset by a higher postoperative mortality (in-hospital or 30-day postoperative death).",
"   </p>",
"   <p>",
"    Meta-analyses of neoadjuvant chemoradiotherapy for esophageal cancer are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link&amp;anchor=H14#H14\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Meta-analyses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3447188\">",
"    <span class=\"h2\">",
"     Intensified preoperative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consistent finding in many studies is that response to preoperative therapy, particularly the absence of residual disease in the surgical specimen (ie, a pathologic complete response), is an indicator of better disease-free and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/57\">",
"     57",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    These data provide the rationale for intensification of preoperative treatment using induction chemotherapy plus neoadjuvant chemoradiotherapy, or using combinations of drugs with greater radiosensitizing potential during concurrent chemoradiotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link&amp;anchor=H336671859#H336671859\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Intensification of preoperative therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early results from trials examining the benefit of preoperative treatment intensification are encouraging but whether the added toxicity is counterbalanced by substantial survival gains is unclear. Phase III trials are needed to confirm the benefit of these more toxic approaches over other more standard regimens such as",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"     /FU",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"      carboplatin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"      paclitaxel",
"     </a>",
"     .",
"    </span>",
"    This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link&amp;anchor=H336671859#H336671859\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Intensification of preoperative therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5372117\">",
"    <span class=\"h2\">",
"     Neoadjuvant chemoradiotherapy versus chemotherapy alone",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3447368\">",
"    <span class=\"h3\">",
"     German POET trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The multicenter German POET (PreOperative chemotherapy or radiochemotherapy in Esophagogastric adenocarcinoma Trial) was the first",
"    <sup>",
"    </sup>",
"    attempt at a randomized study limited exclusively to patients",
"    <sup>",
"    </sup>",
"    with adenocarcinomas of the EGJ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/40\">",
"     40",
"    </a>",
"    ]. It is also the only phase III trial directly comparing neoadjuvant chemoradiotherapy versus chemotherapy alone.",
"   </p>",
"   <p>",
"    Patients with locally advanced (EUS-staged T3-4,NX,M0) adenocarcinoma of",
"    <sup>",
"    </sup>",
"    the lower esophagus, EGJ or gastric cardia were randomly allocated",
"    <sup>",
"    </sup>",
"    to neoadjuvant chemotherapy (15 weeks of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once every other week), FU (2000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 24 hours weekly) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over two hours weekly) followed by surgery, or induction chemotherapy (12 weeks of the same cisplatin, leucovorin and FU regimen followed",
"    <sup>",
"    </sup>",
"    by three weeks of concurrent chemoradiotherapy) followed by surgery. Concurrent chemoradiotherapy consisted of RT (30 Gy) in daily 2-Gy fractions over three weeks, concurrent with cisplatin (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 and 8) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 3 through 5). The study was closed prematurely after only 126 of the planned 354 patients were randomized because of poor accrual.",
"   </p>",
"   <p>",
"    There was a trend toward higher postoperative mortality rates in patients who received preoperative chemoradiotherapy (10.2 versus 3.8 percent; p=0.26).",
"    <sup>",
"    </sup>",
"    The rate of complete (R0) resection was similar with chemoradiotherapy and chemotherapy (72 versus 70 percent) but the pathologic complete response rate was higher with chemoradiotherapy (16 versus 2 percent), as was the rate of negative lymph nodes (64 versus 38 percent). At a median follow-up of 46 months, there was a trend toward improved three-year survival with chemoradiotherapy (47 versus 28 percent; p=0.07).",
"   </p>",
"   <p>",
"    The local failure rate in the chemotherapy alone group was high (41 percent), a finding that has been reported by others when radiation was not a component of trimodality therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/42\">",
"     42",
"    </a>",
"    ], but not universally. In the MAGIC trial of perioperative chemotherapy, for example, in which neither group received RT, local failure rates with surgery alone and with perioperative chemotherapy were 21 and 14 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18787448\">",
"     'MAGIC trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    While suggestive, these data do not provide definitive proof of the superiority of neoadjuvant chemoradiotherapy over preoperative chemotherapy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3089144\">",
"    <span class=\"h3\">",
"     Australian trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only other trial that addresses the relative benefits of preoperative chemotherapy versus chemoradiotherapy was a randomized phase II Australian trial involving 75 patients with adenocarcinoma of the esophagus or EGJ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/58\">",
"     58",
"    </a>",
"    ]. Although the histopathologic response rate and rate of margin-negative resections favored chemoradiotherapy, median overall survival was not significantly better (32 versus 29 months).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3089229\">",
"    <span class=\"h3\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;These two trials were subjected to a meta-analysis; the HR for all-cause mortality was 0.77 in favor of chemoradiotherapy, but this was not statistically significant (95% CI 0.53-1.12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the relative benefits of preoperative chemotherapy versus chemoradiotherapy remain uncertain. Additional information will be forthcoming from a randomized trial, the TOPGEAR trial, that is currently underway in Europe and Canada to directly compare preoperative chemotherapy alone (ECF) versus chemoradiotherapy (two cycles of ECF followed by concurrent fluoropyrimidine-based chemoradiotherapy) in patients with resectable adenocarcinoma of the stomach and EGJ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/59\">",
"     59",
"    </a>",
"    ]. Both groups will receive three further cycles of ECF postoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1035777\">",
"    <span class=\"h2\">",
"     Adjuvant chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the trials evaluating adjuvant chemoradiotherapy are &ldquo;lower tract&rdquo; trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=see_link&amp;anchor=H2#H2\">",
"     \"Adjuvant and neoadjuvant treatment of gastric cancer\", section on 'Adjuvant chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1035805\">",
"    <span class=\"h3\">",
"     Intergroup Trial 0116",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most influential trial is US Intergroup study INT-0116, which randomly assigned 556 patients with potentially curatively resected T1-4, N0 or 1 (",
"    <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57916 \" href=\"mobipreview.htm?11/6/11374\">",
"     table 3",
"    </a>",
"    ) gastric or EGJ adenocarcinoma (20 percent of all enrollees) to observation alone or adjuvant-combined chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/35\">",
"     35",
"    </a>",
"    ]. Treatment consisted of one cycle of 5-FU (425",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    calcium (20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) daily for five days, followed one month later by 45 Gy (1.8",
"    <span class=\"nowrap\">",
"     Gy/day)",
"    </span>",
"    RT given with FU and leucovorin calcium (400",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    respectively) on days 1 through 4 and on the last three days of RT. Two additional five-day cycles of chemotherapy (5-FU 425",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day and leucovorin calcium 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) were given at monthly intervals beginning one month after completion of RT.",
"   </p>",
"   <p>",
"    Three-year disease-free and overall survival rates (50 versus 41 percent) were significantly better with combined modality therapy, as was median survival (36 versus 27 months), despite the fact that only 64 percent of all patients could complete all of the planned treatment. Patients with EGJ tumors appeared to derive the same benefit as did those with non-cardia gastric cancer. Results from this trial, including treatment-related toxicity, are described in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=see_link&amp;anchor=H2#H2\">",
"     \"Adjuvant and neoadjuvant treatment of gastric cancer\", section on 'Adjuvant chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These results changed the standard of care in the US for patients undergoing potentially curative resection of stage IIA or higher gastric cancer (",
"    <a class=\"graphic graphic_table graphicRef57916 \" href=\"mobipreview.htm?11/6/11374\">",
"     table 3",
"    </a>",
"    ) from observation alone to adjuvant chemoradiotherapy. While this approach is still used in patients who undergo initial surgery for an EGJ adenocarcinoma, in contemporary practice, at least in the US, EGJ tumors are more often approached with neoadjuvant chemotherapy with or without RT than with upfront surgery followed by adjuvant therapy. (See",
"    <a class=\"local\" href=\"#H18787489\">",
"     'Neoadjuvant concurrent chemoradiotherapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18787392\">",
"     'Perioperative chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1035812\">",
"    <span class=\"h3\">",
"     CALGB 80101",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal chemoradiotherapy regimen for use in the adjuvant setting is not established.",
"   </p>",
"   <p>",
"    As noted above, the MAGIC trial demonstrated a significant survival benefit for the use of perioperative chemotherapy with ECF versus surgery alone. (See",
"    <a class=\"local\" href=\"#H18787448\">",
"     'MAGIC trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    CALGB 80101, a US Intergroup study, compared the INT-0116 protocol regimen (bolus FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    with FU plus concurrent RT) versus postoperative ECF before and after FU plus concurrent RT in 546 patients with completely resected gastric or EGJ tumors that extended beyond the muscularis propria or were node-positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/60\">",
"     60",
"    </a>",
"    ]. The percentage with EGJ tumors was not reported. In a preliminary report presented at the 2011 ASCO meeting, the ECF-containing arm had lower rates of diarrhea, mucositis, and grade 4 or worse neutropenia. However, overall survival, the primary endpoint, was not significantly better with ECF (at three years, 52 versus 50 percent for",
"    <span class=\"nowrap\">",
"     FU/LV).",
"    </span>",
"    This trial is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=see_link&amp;anchor=H3744529#H3744529\">",
"     \"Adjuvant and neoadjuvant treatment of gastric cancer\", section on 'Choice of regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The chemoradiotherapy regimen as used in INT-0116 remains a standard option when adjuvant chemoradiotherapy is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1037943\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant survival benefit for adjuvant chemotherapy in resected gastric cancer is supported by at least four meta-analyses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=see_link&amp;anchor=H23495743#H23495743\">",
"     \"Adjuvant and neoadjuvant treatment of gastric cancer\", section on 'Adjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials exploring the benefit of adjuvant chemotherapy in patients with esophageal or EGJ adenocarcinoma. Benefit for adjuvant chemotherapy alone was suggested in an uncontrolled trial conducted by the Eastern Cooperative Oncology Group that included patients with distal esophageal (n = 9), EGJ (n = 34) or gastric cardia (n = 12) tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/61\">",
"     61",
"    </a>",
"    ]. Eligible patients had either T2N1-2 or T3 or 4 disease that was completely resected with negative margins; 49 (89 percent) were node-positive. Treatment consisted of four three-week cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </span>",
"    With a median follow-up of four years, the three-year survival rate was 44 percent. While these results compare favorably with historical series, the lack of a surgery alone control group precludes interpretation of these data. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H942268\">",
"    <span class=\"h2\">",
"     Selecting the therapeutic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because cancers of the EGJ have been included in studies of both gastric (lower) and esophageal (upper) cancer, it remains challenging to define an optimal approach for this cohort of patients. With the single exception of the POET trial, perioperative chemotherapy, preoperative chemoradiotherapy and postoperative chemoradiotherapy have never been directly compared to each other. Furthermore, across these approaches, only the POET trial focused exclusively on the EGJ group. (See",
"    <a class=\"local\" href=\"#H3447368\">",
"     'German POET trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, on balance, there is a sound rationale for considering chemotherapy with or without RT prior to surgery for tumors of the EGJ:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary tumor and systemic micrometastatic disease can be treated simultaneously.",
"     </li>",
"     <li>",
"      Baseline dysphagia might improve, thus increasing the patient&rsquo;s ability to tolerate major surgery.",
"     </li>",
"     <li>",
"      The overall ability to tolerate chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      radiotherapy is superior in the preoperative setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]; the ability to deliver postoperative therapy may be compromised by surgical complications.",
"     </li>",
"     <li>",
"      Pathologic complete responses, or major responses, which are known predictors of improved survival after surgery, may be attained. (See",
"      <a class=\"local\" href=\"#H3447188\">",
"       'Intensified preoperative therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rate of microscopically complete (R0) resection may be improved. However, whether initially unresectable or borderline resectable disease may become subsequently resectable following initial chemotherapy or chemoradiotherapy is a controversial area. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=see_link&amp;anchor=H28#H28\">",
"       \"Management of locally advanced unresectable esophageal cancer\", section on 'Post-chemoradiotherapy surgery'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For these reasons we generally prefer the neoadjuvant approach for most patients. However, surgery might be considered first for a clearly resectable tumor when there is concern that the patient might not tolerate preoperative therapy. Initial surgery is also appropriate if the preoperative staging evaluation suggests a T1N0 tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1292688\">",
"    <span class=\"h3\">",
"     Neoadjuvant approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials and meta-analyses demonstrate that concomitant chemoradiotherapy followed by surgery provides a survival benefit compared to surgery alone; further, local control appears to be better with preoperative chemoradiotherapy compared to surgery alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/54,62\">",
"     54,62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18787489\">",
"     'Neoadjuvant concurrent chemoradiotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Induction chemotherapy without RT also provides a significant survival benefit over surgery alone, and this approach has been adopted in the United Kingdom based upon the MRC and MAGIC trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/34,46\">",
"     34,46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18787392\">",
"     'Perioperative chemotherapy'",
"    </a>",
"    above.)",
"    <br/>",
"    <br/>",
"    A single randomized trial comparing preoperative chemotherapy to preoperative sequential chemotherapy followed by chemoradiotherapy in patients with EGJ adenocarcinoma suggests that the likelihood of a complete pathologic response is higher with in patients who receive neoadjuvant RT, and that survival might also be superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/40\">",
"     40",
"    </a>",
"    ]. Furthermore, local failure rates may also be lower in patients treated with chemoradiotherapy followed by surgery compared to those receiving chemotherapy followed by surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/54,63\">",
"     54,63",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5372117\">",
"     'Neoadjuvant chemoradiotherapy versus chemotherapy alone'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For all of these reasons, we favor neoadjuvant concurrent chemoradiotherapy for a T2 or higher, or node-positive localized adenocarcinomas of the EGJ, particularly if the patient has bulky tumor involvement (ie, paraesophageal lymph nodes &gt;2 cm; obstructing tumor; celiac lymphadenopathy) or initially appears to be borderline resectable since a high response rate might increase the likelihood of a successful resection. Consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    state a preference for preoperative chemoradiotherapy over preoperative chemotherapy alone for patients with EGJ adenocarcinoma.",
"   </p>",
"   <p>",
"    We tend to prefer the CROSS approach (weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    [AUC of 2] plus concurrent RT [41.4 Gy over five weeks]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/53\">",
"     53",
"    </a>",
"    ], although the regimen used in CALGB 9781 is also reasonable (50.4 Gy external beam RT in 1.8 daily fractions, five days per week, and concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 29) and infusional FU (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day by continuous infusion for 96 hours, days 1 through 4 and 29 through 32, after cisplatin) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5373124\">",
"     'CROSS trial'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3089538\">",
"     'CALGB 9781'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Issues related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    dosing (ie, estimation of glomerular filtration rate, dose calculation for obese patients) are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H7#H7\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'AUC dose calculation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, perioperative chemotherapy is a reasonable approach for patients who cannot tolerate trimodality therapy, and might be favored when there is a high clinical suspicion of occult metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5353223\">",
"    <span class=\"h4\">",
"     Use of PET and PET-CT during treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited experience suggests that whole-body",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging detects distant metastases in approximately 8 percent of patients following induction chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/64\">",
"     64",
"    </a>",
"    ]. In many of these cases, the metastases have been located in sites (eg, skeletal muscle, subcutaneous soft tissue, brain, thyroid) that are not imaged well by conventional staging radiographic evaluation.",
"   </p>",
"   <p>",
"    In addition to detecting otherwise occult metastatic disease, early metabolic responses observed on PET scans during induction chemotherapy may have significant predictive and prognostic benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. As an example, the phase II MUNICON study showed that, among patients with adenocarcinomas of the esophagus or EGJ who underwent PET scanning two weeks after beginning neoadjuvant chemotherapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and FU, metabolic responders had a significantly better prognosis than did nonresponders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, PET-directed therapy cannot yet be considered a standard approach for any esophageal cancer. One problem is that the best way to measure metabolic response to induction chemotherapy or chemoradiotherapy in esophageal cancer has not been well established. In addition, whether",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    outperforms CT or EUS for assessment of response to preoperative therapy is unclear; the available data are conflicting. Finally, it is not clear whether a change in therapy will improve prognosis in nonresponders. An upcoming US cooperative group trial (CALGB 80803) will use the results of post-induction chemotherapy PET scanning to determine the choice of the chemotherapy regimen during subsequent chemoradiotherapy, followed by surgery.",
"   </p>",
"   <p>",
"    We typically order a post-induction therapy",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    no earlier than four weeks after the completion of induction therapy only as a method to assess for distant metastatic disease, an approach that is also endorsed in the consensus-based",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines. If a new lesion is identified, a biopsy is performed. The use of post-induction therapy",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scanning for esophageal cancer is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link&amp;anchor=H20504361#H20504361\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Utility of postinduction therapy PET scans'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis and staging of esophageal cancer\", section on 'PET restaging after initial induction therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3447444\">",
"    <span class=\"h4\">",
"     Management of postoperative residual disease after neoadjuvant therapy and surgery",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3447505\">",
"    <span class=\"h5\">",
"     After chemotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who undergo preoperative chemotherapy, an unanswered question is whether postoperative chemoradiotherapy would confer additional benefit, particularly in the setting of multiply positive nodes. Perioperative chemotherapy decreases the risk of metastatic disease but does not have as great an effect on locoregional control as does chemoradiotherapy. This question is currently being addressed in the Dutch CRITICs (ChemoRadiotherapy after Induction chemoTherapy In Cancer of the Stomach) trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/67\">",
"     67",
"    </a>",
"    ], where patients with gastric cancer are randomly assigned to six cycles of perioperative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (ECX) chemotherapy (three before and three after) versus three cycles of preoperative ECX followed by postoperative chemoradiotherapy. Patients with EGJ tumors are eligible, as long as their main tumor bulk is in the stomach.",
"   </p>",
"   <p>",
"    Consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    suggest postoperative chemoradiotherapy or ECF or its modifications if used preoperatively for patients who have residual node-positive or T3 disease after preoperative chemotherapy. If we are treating off-protocol as per the MAGIC trial, our approach is to use the same chemotherapy as was given preoperatively and administer three postoperative cycles. (See",
"    <a class=\"local\" href=\"#H18787448\">",
"     'MAGIC trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3447512\">",
"    <span class=\"h5\">",
"     After chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with residual primary tumor or extensive nodal disease after preoperative chemoradiotherapy is also uncertain. Administering additional postoperative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and FU chemotherapy has proven difficult due to therapy intolerance. Data from at least three trials (RTOG 85-01, US INT 0116, and the MAGIC trial) indicate only a 50 to 60 percent rate of delivery of planned postoperative or postradiotherapy chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/34,35,68\">",
"     34,35,68",
"    </a>",
"    ]. In addition to concerns as to tolerability, the potential for added benefit from more of the same preoperative treatment in patients with extensive residual disease is open to question.",
"   </p>",
"   <p>",
"    Management must be individualized based upon the clinical circumstances. Our approach for many patients with a minimal pathologic response to preoperative chemoradiotherapy is to attempt to administer chemotherapy with different agents than those given preoperatively (eg, ECF if the initial chemoradiotherapy regimen included only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and FU). There are no consensus-based recommendations from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    in this regard.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1292845\">",
"    <span class=\"h3\">",
"     Indications for adjuvant therapy for patients treated with initial surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with completely resected T2N1-2 or T3 or 4 EGJ adenocarcinoma who have not received neoadjuvant therapy, we typically recommend postoperative adjuvant therapy. It is difficult to come to any conclusions as to whether there are specific advantages for adjuvant chemoradiotherapy over chemotherapy alone. In our view, either approach is reasonable. Further confirmatory trials, particularly randomized trials, are necessary before specific recommendations can be made. We tend to favor chemoradiotherapy (as per the INT 0116 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/35\">",
"     35",
"    </a>",
"    ]) unless a patient is deemed unlikely to tolerate chemoradiotherapy",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H942275\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials to guide the postoperative surveillance strategy and no data that demonstrate improvement in quality of life or longevity from earlier detection of asymptomatic recurrences. Nevertheless, consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History and physical examination every three to six months for one to two years, then every six to 12 months for years three to 5, then annually",
"     </li>",
"     <li>",
"      CBC and chemistry profile, as clinically indicated",
"     </li>",
"     <li>",
"      Radiologic imaging and upper GI endoscopy, as clinically indicated.",
"     </li>",
"     <li>",
"      Dilation for anastomotic stenosis",
"     </li>",
"     <li>",
"      Nutritional counseling",
"     </li>",
"     <li>",
"      Confirm that HER2 testing has been done if metastatic disease was present at diagnosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44202?source=see_link&amp;anchor=H34#H34\">",
"     \"Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer\", section on 'Agents targeting HER2'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some clinicians check tumor markers (particularly carcinoembryonic antigen [CEA]) with each follow-up up visit, if initially elevated, and perform restaging CT scans every three to six months, at least for the first two years. However, the utility of tumor marker and radiographic surveillance is controversial. Although early detection of recurrence can facilitate treatment before the development of symptomatic bulky disease that may be difficult to manage (eg, bowel entrapment from peritoneal metastases), there are no data that support the view that early detection of an asymptomatic recurrence by tumor marker elevation or radiologic imaging improves quality of life or prolongs survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Nevertheless, patients tend to better candidates for chemotherapy protocols when their metastatic disease is diagnosed earlier rather than later.",
"   </p>",
"   <p>",
"    At our institution, we perform history, physical examination and targeted blood work (for a symptomatic patient, or if there was a serum tumor marker that was elevated preoperatively) every four months for the first three years and also perform restaging CT scans of the chest and abdomen at four month intervals.",
"   </p>",
"   <p>",
"    We do not carry out surveillance endoscopy unless there was a preoperative history of Barrett's esophagus, a questionable margin at the time of surgery, or if the patient has a recalcitrant stricture that is worrisome for an occult local recurrence.",
"   </p>",
"   <p>",
"    When planning the posttreatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/17/9491?source=see_link\">",
"       \"Patient information: Esophageal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18787496\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenocarcinoma of the esophagogastric junction (EGJ) is the most rapidly increasing tumor in the Western world. (See",
"      <a class=\"local\" href=\"#H18787235\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The latest (7",
"      <sup>",
"       th",
"      </sup>",
"      ) edition of the AJCC staging manual defines EGJ tumors as those tumors arising at the EGJ or in the cardia of the stomach within 5 cm of the EGJ that extend into the EGJ or esophagus (",
"      <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/6\">",
"       6",
"      </a>",
"      ]. EGJ cancers are all staged as esophageal rather than gastric cancers. (See",
"      <a class=\"local\" href=\"#H497521\">",
"       'AJCC classification'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link\">",
"       \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Siewert described three distinct categories of EGJ adenocarcinoma based upon anatomic location (",
"      <a class=\"graphic graphic_figure graphicRef64783 \" href=\"mobipreview.htm?32/24/33159\">",
"       figure 3",
"      </a>",
"      ). The Siewert classification is useful for guiding the surgical strategy, but not for selection of the specific multimodality approach. (See",
"      <a class=\"local\" href=\"#H12477151\">",
"       'Siewert classification'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link\">",
"       \"Surgical oncologic principles for management of resectable esophageal cancer\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      The diagnosis of an EGJ or gastric cardia carcinoma is usually established by endoscopic biopsy. The staging evaluation usually begins with a contrast-enhanced helical CT scan. Patients without evidence of metastatic disease undergo endoscopic ultrasonography (EUS) for locoregional staging. Integrated",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      is useful to detect metastatic disease in patients who are otherwise believed to be surgical candidates after conventional CT and EUS. Suspicious PET findings should be confirmed with biopsy before excluding a patient from surgical consideration. (See",
"      <a class=\"local\" href=\"#H944333\">",
"       'Pretreatment staging evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link&amp;anchor=H7377444#H7377444\">",
"       \"Surgical oncologic principles for management of resectable esophageal cancer\", section on 'Esophagogastric junction cancer resection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is no consensus on the role of staging laparoscopy. We perform diagnostic laparoscopy for patients with potentially resectable clinical T3 or T4 (",
"      <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"       table 1",
"      </a>",
"      ) or Siewert II-III tumors at the EGJ, or if there is suspicion for intraperitoneal metastatic disease that cannot otherwise be confirmed. (See",
"      <a class=\"local\" href=\"#H3443822\">",
"       'Diagnostic laparoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although complete surgical resection is a prerequisite for cure, long-term outcomes are not satisfactory with resection alone, even if microscopically complete (R0). Multimodality treatment improves outcomes, and has become a standard approach for patients with T2 and higher (",
"      <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"       table 1",
"      </a>",
"      ), or node-positive adenocarcinoma of the EGJ. (See",
"      <a class=\"local\" href=\"#H7932647\">",
"       'Evolution of treatment philosophy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The best form of multimodality therapy is not established. Areas of debate include the relative benefits of perioperative chemotherapy versus preoperative chemoradiotherapy versus initial surgery followed by postoperative chemoradiotherapy or chemotherapy, and the specific drug regimen to be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1035448\">",
"    <span class=\"h2\">",
"     Recommended approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following represents our general approach to therapy in patients with adenocarcinoma of the EGJ:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We generally prefer neoadjuvant therapy for most patients. However, surgery might be considered first for a clearly resectable tumor when there is concern that the patient might not tolerate preoperative therapy, or if the preoperative staging evaluation suggests a T1N0 tumor. (See",
"      <a class=\"local\" href=\"#H942268\">",
"       'Selecting the therapeutic approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend combined modality therapy rather than rather than surgery alone for patients with T2 or higher or node-positive adenocarcinoma of the EGJ or gastric cardia (",
"      <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"       table 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We suggest preoperative chemoradiotherapy rather than perioperative chemotherapy for most patients who can tolerate the combined modality approach (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). These recommendations follow those of the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       National Comprehensive Cancer Network (NCCN)",
"      </a>",
"      for T1bN1, and T2-T4, N0-1 esophageal and EGJ cancer (",
"      <a class=\"graphic graphic_table graphicRef52078 \" href=\"mobipreview.htm?4/24/4494\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Perioperative chemotherapy is a reasonable approach for patients who cannot tolerate trimodality therapy, and might be favored when there is a high clinical suspicion of occult metastatic disease. Options include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      (ECF) chemotherapy as was used in the MAGIC trial (",
"      <a class=\"graphic graphic_table graphicRef62502 \" href=\"mobipreview.htm?35/44/36558\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/34\">",
"       34",
"      </a>",
"      ], or infusional FU plus cisplatin, as was used in the French",
"      <span class=\"nowrap\">",
"       FNLCC/FFCD",
"      </span>",
"      trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18787448\">",
"       'MAGIC trial'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18787463\">",
"       'French FNLCC/FFCD trial'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The benefit of neoadjuvant therapy for patients with T1N0 EGJ adenocarcinoma is less clear. We recommend surgery alone in these patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Definitive chemoradiotherapy is a reasonable approach for patients who are not surgical candidates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the optimal type, dose, combination, and schedule of drugs for use during concurrent chemoradiotherapy is not established, we suggest multiagent rather than single agent chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Options for the concurrent chemotherapy regimen include two courses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and 5-FU as per the CALGB 9781 trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/55\">",
"       55",
"      </a>",
"      ], or low-dose weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      regimen as was used in the Dutch CROSS trial (",
"      <a class=\"graphic graphic_table graphicRef68266 \" href=\"mobipreview.htm?2/49/2846\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/51/39738/abstract/53\">",
"       53",
"      </a>",
"      ]. We prefer the CROSS regimen. (See",
"      <a class=\"local\" href=\"#H3089538\">",
"       'CALGB 9781'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5373124\">",
"       'CROSS trial'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43378?source=see_link\">",
"       \"Treatment protocols for esophagogastric cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The optimal dose-fractionation RT schedule for concurrent chemoradiotherapy regimens remains to be determined. However, 3-D conformal techniques should be used for modern treatment planning to minimize toxicities to adjacent vital organs (ie, heart, lung, spinal cord, or liver). A standard dose of radiation for patients treated with concurrent FU and cisplatin is 50.4 Gy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link&amp;anchor=H28#H28\">",
"       \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\", section on 'Optimal dose and fractionation schedules'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Following chemoradiotherapy, we perform post-induction therapy integrated",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      no earlier than four weeks after the completion of induction therapy as a method to assess for distant metastatic disease. If a new lesion is identified, biopsy must be performed before excluding a patient from surgical consideration given the high rate of false positive findings. (See",
"      <a class=\"local\" href=\"#H5353223\">",
"       'Use of PET and PET-CT during treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The surgical approach should be based upon anatomic tumor location. (See",
"      <a class=\"local\" href=\"#H12480650\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=see_link&amp;anchor=H89045791#H89045791\">",
"       \"Surgical oncologic principles for management of resectable esophageal cancer\", section on 'Principles of surgical resection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with Siewert type I tumors are not appropriate candidates for a purely transabdominal approach to surgical resection. The standard surgical approach is a transthoracic en bloc esophagectomy and partial gastrectomy with two-field lymphadenectomy.",
"     </li>",
"     <li>",
"      For the majority of Siewert type II and III tumors, total gastrectomy with a",
"      <span class=\"nowrap\">",
"       transabdominal/transhiatal",
"      </span>",
"      resection of the distal esophagus with lymphadenectomy of the lower mediastinum and the abdominal D2 nodal compartment is adequate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resection is generally considered integral to achieving cure in patients with esophageal and EGJ cancers.",
"      <br/>",
"      Definitive chemoradiotherapy is a reasonable approach for patients who are not surgical candidates but is less desirable as curative therapy for adenocarcinoma. (See",
"      <a class=\"local\" href=\"#H13892529\">",
"       'Necessity for surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of patients who have extensive residual disease in the surgical specimen after neoadjuvant chemotherapy or chemoradiotherapy is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who undergo surgery after preoperative chemotherapy alone, we suggest postoperative chemotherapy rather than chemoradiotherapy, if the perioperative MAGIC trial approach (ie, ECF chemotherapy, (",
"      <a class=\"graphic graphic_table graphicRef62502 \" href=\"mobipreview.htm?35/44/36558\">",
"       table 2",
"      </a>",
"      )) is being used (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Consensus-based guidelines from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      suggest postoperative chemoradiotherapy or ECF or its modifications if used preoperatively for patients who have residual node-positive or T3 disease after preoperative chemotherapy. (See",
"      <a class=\"local\" href=\"#H3447505\">",
"       'After chemotherapy alone'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43378?source=see_link\">",
"       \"Treatment protocols for esophagogastric cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The best approach to patients with a minimal pathologic response to preoperative chemoradiotherapy is uncertain, and decisions must be individualized based upon the clinical circumstances. Guidelines are not available from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H3447512\">",
"       'After chemoradiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who undergo initial surgery rather than neoadjuvant therapy, we recommend postoperative adjuvant chemoradiotherapy for those with node-positive disease or a T2 or higher primary tumor stage (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). &nbsp;Chemotherapy alone is a reasonable option for patients who cannot tolerate chemoradiotherapy. (See",
"      <a class=\"local\" href=\"#H1035777\">",
"       'Adjuvant chemoradiotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1037943\">",
"       'Adjuvant chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no randomized trials to guide the postoperative surveillance strategy and no data that demonstrate improvement in quality of life or longevity from earlier detection of asymptomatic recurrences. Consensus-based guidelines for posttreatment surveillance are available from the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       NCCN",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H942275\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/2\">",
"      M&ouml;nig SP, H&ouml;lscher AH. Clinical classification systems of adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res 2010; 182:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/3\">",
"      Ectors N, Driessen A, De Hertog G, et al. Is adenocarcinoma of the esophagogastric junction or cardia different from Barrett adenocarcinoma? Arch Pathol Lab Med 2005; 129:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/4\">",
"      Chandrasoma P, Makarewicz K, Wickramasinghe K, et al. A proposal for a new validated histological definition of the gastroesophageal junction. Hum Pathol 2006; 37:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/5\">",
"      Misumi A, Murakami A, Harada K, et al. Definition of carcinoma of the gastric cardia. Langenbecks Arch Chir 1989; 374:221.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge S, Byrd, DR, Compton, CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/7\">",
"      Siewert JR, H&ouml;lscher AH, Becker K, G&ouml;ssner W. [Cardia cancer: attempt at a therapeutically relevant classification]. Chirurg 1987; 58:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/8\">",
"      Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/9\">",
"      Mariette C, Piessen G, Briez N, et al. Oesophagogastric junction adenocarcinoma: which therapeutic approach? Lancet Oncol 2011; 12:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/10\">",
"      Hasegawa S, Yoshikawa T, Aoyama T, et al. Esophagus or stomach? The seventh TNM classification for Siewert type II/III junctional adenocarcinoma. Ann Surg Oncol 2013; 20:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/11\">",
"      R&uuml;diger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000; 232:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/12\">",
"      Fang WL, Wu CW, Chen JH, et al. Esophagogastric junction adenocarcinoma according to Siewert classification in Taiwan. Ann Surg Oncol 2009; 16:3237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/13\">",
"      Hasegawa S, Yoshikawa T, Cho H, et al. Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center. World J Surg 2009; 33:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/14\">",
"      Meier I, Merkel S, Papadopoulos T, et al. Adenocarcinoma of the esophagogastric junction: the pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definition. Int J Radiat Oncol Biol Phys 2008; 70:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/15\">",
"      Hasegawa S, Yoshikawa T. Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer 2010; 13:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/16\">",
"      Hansen S, Vollset SE, Derakhshan MH, et al. Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. Gut 2007; 56:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/17\">",
"      McColl KE, Going JJ. Aetiology and classification of adenocarcinoma of the gastro-oesophageal junction/cardia. Gut 2010; 59:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/18\">",
"      Derakhshan MH, Malekzadeh R, Watabe H, et al. Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. Gut 2008; 57:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/19\">",
"      Ren JS, Kamangar F, Qiao YL, et al. Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut 2009; 58:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/20\">",
"      Hosokawa Y, Kinoshita T, Konishi M, et al. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan. Ann Surg Oncol 2012; 19:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/21\">",
"      Barbour AP, Rizk NP, Gerdes H, et al. Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction. J Am Coll Surg 2007; 205:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/22\">",
"      Weinberg JS, Suki D, Hanbali F, et al. Metastasis of esophageal carcinoma to the brain. Cancer 2003; 98:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/23\">",
"      Gabrielsen TO, Eldevik OP, Orringer MB, Marshall BL. Esophageal carcinoma metastatic to the brain: clinical value and cost-effectiveness of routine enhanced head CT before esophagectomy. AJNR Am J Neuroradiol 1995; 16:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/24\">",
"      Smith RS, Miller RC. Incidence of brain metastasis in patients with esophageal carcinoma. World J Gastroenterol 2011; 17:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/25\">",
"      Stahl M, Oliveira J, ESMO Guidelines Working Group. Esophageal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/26\">",
"      Hori Y, SAGES Guidelines Committee. Diagnostic laparoscopy guidelines : This guideline was prepared by the SAGES Guidelines Committee and reviewed and approved by the Board of Governors of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), November 2007. Surg Endosc 2008; 22:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/27\">",
"      Cordin J, Lehmann K, Schneider PM. Clinical staging of adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res 2010; 182:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/28\">",
"      Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/29\">",
"      Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/30\">",
"      Vial M, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res 2010; 182:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/31\">",
"      Hansen S, Wiig JN, Giercksky KE, Tretli S. Esophageal and gastric carcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subsites. Int J Cancer 1997; 71:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/32\">",
"      Apisarnthanarax S, Tepper JE. Crossroads in the combined-modality management of gastroesophageal junction carcinomas. Gastrointest Cancer Res 2008; 2:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/33\">",
"      Tepper JE, O'Neil B. Transition in biology and philosophy in the treatment of gastroesophageal junction adenocarcinoma. J Clin Oncol 2009; 27:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/34\">",
"      Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/35\">",
"      Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/36\">",
"      Whiteman DC, Parmar P, Fahey P, et al. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology 2010; 139:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/37\">",
"      Leers JM, DeMeester SR, Chan N, et al. Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus. J Thorac Cardiovasc Surg 2009; 138:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/38\">",
"      Whitson BA, Groth SS, Li Z, et al. Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas. J Thorac Cardiovasc Surg 2010; 139:43.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.103.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/40\">",
"      Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/41\">",
"      Paulson EC, Ra J, Armstrong K, et al. Underuse of esophagectomy as treatment for resectable esophageal cancer. Arch Surg 2008; 143:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/42\">",
"      Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/43\">",
"      Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/44\">",
"      Orringer MB, Marshall B, Iannettoni MD. Transhiatal esophagectomy: clinical experience and refinements. Ann Surg 1999; 230:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/45\">",
"      Rice TW, Rusch VW, Apperson-Hansen C, et al. Worldwide esophageal cancer collaboration. Dis Esophagus 2009; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/46\">",
"      Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/47\">",
"      Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27:5062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/48\">",
"      Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/49\">",
"      Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28:5210.",
"     </a>",
"    </li>",
"    <li>",
"     Data presented at the Annual meeting of the American Society of Clinical Oncology, Orlando, FL, May 15, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/51\">",
"      Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/52\">",
"      Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335:462.",
"     </a>",
"    </li>",
"    <li>",
"     Gaast AV, van Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric cancer: Results from a multinational randomized phase III study (abstract 4004). J Clin Oncol 2010; 28:302s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/54\">",
"      Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/55\">",
"      Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26:1086.",
"     </a>",
"    </li>",
"    <li>",
"     Mariette C, Seitz JF, Maillard E, et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901 (abstract 4005). J Clin Oncol 2010; 28:302s. file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=52216 (Accessed on February 19, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/57\">",
"      Fields RC, Strong VE, G&ouml;nen M, et al. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer 2011; 104:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/58\">",
"      Burmeister BH, Thomas JM, Burmeister EA, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 2011; 47:354.",
"     </a>",
"    </li>",
"    <li>",
"     Leong T, et al. TOPGEAR: an international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG). J clin Oncol 30, 2012 (suppl; abstr TPS4141). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=99024 (Accessed on June 14, 2012).",
"    </li>",
"    <li>",
"     Fuchs CS, Tepper JE, Niedzwiecke D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101 (abstract 4003). J Clin Oncol 2011; 29:256s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=82318 (Accessed on June 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/61\">",
"      Armanios M, Xu R, Forastiere AA, et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol 2004; 22:4495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/62\">",
"      Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/63\">",
"      Kleinberg L, Knisely JP, Heitmiller R, et al. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2003; 56:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/64\">",
"      Bruzzi JF, Swisher SG, Truong MT, et al. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 2007; 109:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/65\">",
"      Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/66\">",
"      Javeri H, Xiao L, Rohren E, et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer 2009; 115:5184.",
"     </a>",
"    </li>",
"    <li>",
"     Information on the Dutch CRITICS trial is available online at file://clinicaltrials.gov/ct2/show/NCT00407186 (Accessed on December 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/68\">",
"      Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/69\">",
"      Eom BW, Ryu KW, Lee JH, et al. Oncologic effectiveness of regular follow-up to detect recurrence after curative resection of gastric cancer. Ann Surg Oncol 2011; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/51/39738/abstract/70\">",
"      Yoon SS. How closely should we follow gastric cancer patients following surgical resection? Ann Surg Oncol 2011; 18:311.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16226 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39738=[""].join("\n");
var outline_f38_51_39738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18787496\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18787235\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7933267\">",
"      DEFINITION AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H497521\">",
"      AJCC classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12477151\">",
"      Siewert classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H944333\">",
"      PRETREATMENT STAGING EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5353119\">",
"      PET and PET-CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3443822\">",
"      Diagnostic laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3444420\">",
"      Indicators of unresectability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7932647\">",
"      EVOLUTION OF TREATMENT PHILOSOPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3446455\">",
"      Epidemiologic changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3446618\">",
"      Multimodality therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13892529\">",
"      - Necessity for surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13892643\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H944579\">",
"      SURGICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12480650\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18787330\">",
"      Outcomes with surgery alone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12480581\">",
"      MULTIMODALITY APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18787392\">",
"      Perioperative chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H944964\">",
"      - Upper GI tract trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H945003\">",
"      - Lower GI tract trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18787448\">",
"      MAGIC trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18787463\">",
"      French FNLCC/FFCD trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3089293\">",
"      - Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18787489\">",
"      Neoadjuvant concurrent chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5373124\">",
"      - CROSS trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3089538\">",
"      - CALGB 9781",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12481359\">",
"      - Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3447188\">",
"      Intensified preoperative therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5372117\">",
"      Neoadjuvant chemoradiotherapy versus chemotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3447368\">",
"      - German POET trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3089144\">",
"      - Australian trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3089229\">",
"      - Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1035777\">",
"      Adjuvant chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1035805\">",
"      - Intergroup Trial 0116",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1035812\">",
"      - CALGB 80101",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1037943\">",
"      Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H942268\">",
"      Selecting the therapeutic approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1292688\">",
"      - Neoadjuvant approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5353223\">",
"      Use of PET and PET-CT during treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3447444\">",
"      Management of postoperative residual disease after neoadjuvant therapy and surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H3447505\">",
"      - After chemotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H3447512\">",
"      - After chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1292845\">",
"      - Indications for adjuvant therapy for patients treated with initial surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H942275\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18787496\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1035448\">",
"      Recommended approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16226\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16226|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/45/4817\" title=\"figure 1\">",
"      Parts of the stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/63/11263\" title=\"figure 2\">",
"      Landmarks diagnosis Barretts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/24/33159\" title=\"figure 3\">",
"      Definition and extent of resection for adenocarcinoma of the EGJ",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16226|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/32/44557\" title=\"picture 1\">",
"      Barretts esophagus Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16226|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/24/4494\" title=\"table 1\">",
"      TNM staging esoph adenoCA including EGJ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/44/36558\" title=\"table 2\">",
"      ECF for advanced esophagogastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/6/11374\" title=\"table 3\">",
"      2010 TNM staging stomach CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/49/2846\" title=\"table 4\">",
"      Carboplatin and paclitaxel with RT for EGJ cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=related_link\">",
"      Adjuvant and neoadjuvant treatment of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44202?source=related_link\">",
"      Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27208?source=related_link\">",
"      Endoscopic ultrasound in esophageal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4661?source=related_link\">",
"      Epidemiology of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1161?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33018?source=related_link\">",
"      Invasive gastric cancer: Surgery and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=related_link\">",
"      Management of locally advanced unresectable esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20426?source=related_link\">",
"      Management of superficial esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8391?source=related_link\">",
"      Pathogenesis of Barrett's esophagus and its malignant transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/17/9491?source=related_link\">",
"      Patient information: Esophageal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=related_link\">",
"      Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/618?source=related_link\">",
"      Risk factors for gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/30/34282?source=related_link\">",
"      Surgical oncologic principles for management of resectable esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43378?source=related_link\">",
"      Treatment protocols for esophagogastric cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_51_39739="Sources for epidural abscess";
var content_f38_51_39739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sources of infection for spinal epidural abscess",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No source identified",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin and soft tissue",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinal surgery or procedures",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Injection drug use",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other sources, including epidural catheters",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone or joint",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary tract",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper respiratory tract",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdomen",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intravascular catheter associated",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Danner, R, Hartman, BJ, Rev Infect Dis 1975; 9:265; Nussbaum, ES, Rigamonti, D, Standiford, H, et al, Surg Neurol 1992; 38:225; Gellin, BG, Weingarten, K, Gamache, FW Jr, et al. Epidural Abscess. In: Infections of the Central Nervous System, 2nd ed, Scheld, WM, Whitley, RJ, Durack, DT (Eds), Lippincott-Raven Publishers, Philadelphia 1997. p.507; Rigamonti, D, Liem, L, Wolf, AL, et al, Mt Sinai J Med 1994; 61:357; Kapeller, P, Fazekas, F, Krametter, D, et al, Eur Neurol 1997; 38:94.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39739=[""].join("\n");
var outline_f38_51_39739=null;
var title_f38_51_39740="Dyspnea onset";
var content_f38_51_39740=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dyspnea onset",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Acute onset dyspnea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Aspirated foreign body",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Airway trauma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Direct pulmonary injury",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anaphylaxis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Angioedema",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Flash pulmonary edema",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pulmonary embolism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pulmonary hemorrhage",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pneumothorax",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cardiac arrhythmia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acute coronary syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cardiac tamponade*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Organophosphate poisoning",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hyperventilation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anxiety attack",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Gradual onset dyspnea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pharyngeal/neck infections",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pulmonary infection",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sepsis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          High output heart failure",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          HF exacerbation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          COPD exacerbations",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Asthma exacerbations*",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pleural effusion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lung tumor",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          ARDS",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Neuromuscular disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Carbon monoxide poisoning",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diabetic ketoacidosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Salicylate poisoning or other toxin-related acidosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pregnancy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cardiomyopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Valvular dysfunction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ascites",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acute chest syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Intraabdominal process (eg, infection, obstruction, ischemic bowel)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Massive obesity",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *May be acute or gradual in onset.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39740=[""].join("\n");
var outline_f38_51_39740=null;
var title_f38_51_39741="Endotoxemia and atherosclerosis";
var content_f38_51_39741=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Elevated serum endotoxin is associated with carotid atherosclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 357px; background-image: url(data:image/gif;base64,R0lGODlhkQFlAcQAAP///wAzmf8AAAAAAICAgAAZTDMzM6qqqhEREe7u7nd3d38AAIiIiFVVVczMzCIiIkRERJmZmWZmZt3d3bu7u8DAwEBAQAAMJgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACRAWUBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2edxUVn6OkLwQEpamqJqerpRADDiQJDwMKJQcGA7aTra6eB7uxJBAIvCMJCA8JEgMMkr6/ng3DIhIGDMciwQ0AFAPdkdHSnNSyAAwIE9m3Iw4DDwDv4ZDj5JrmIsbC2ui7tRKgobpXrtoIdv7aAUhQbIJAgpqCCaOXsCK1ARDOiRsIsSMlex5DNgIpsiQikiZT/w5CqbLlmW/hEvAbcGAFS5c4w+gCJ0LmgAQubuYc2mVeT34KUwglyhSL0RK6IpCocKoqAQscm2rl8pSEAmdTrZ7CutWO2LNo06pdy3apl6cHwunSiMJtWTQDCujdy7ev37+AAwsuMCDNzl0OJtSCJ9Vm1rtwBgSYTLmy5cuYM2veHKAwILuQy0jmTLq0acue/4AOPWb06dewL6f2s5p1GNexc7+e3ae27S+4dQvnzJuP799dgg9fLjvQceRblDOf3tn5Y+h4qWunXHzPc+xYpG8X3l3Pd/BWxI/PXT7PefRU1K+H3R7Pe/hS5M8/Xf/OffxQ6Ldfaf2ZdR2Atw24XP+BdfyHYBMCKrgZg3Q4+OASEUqYGYVzWHhhEhlq2NxnB37IRYgiVsahHB6aaASKKU62YhwtukgEjDHOCEeNNgqBY4o6vsFjj0D8KGKQbgxJpA9GaohkG0ouyUOTEj7JRpRS6kClglaugWWWOGw5YJc+MMAAQxQN8SWYNoi5H5k9PMDARc8UsSabNLg5H5w7yJSLAdcYcSeeMui5Hp87IPCVAgoYIGiJhD5h6HiI6tAMTQakGcSgkb4w6XaV5pAAAxEkoABdQnDaaQufaheqDQqswyijdRKh6qortErdqzT4edgAjtoJKa5K6DodrzQckAAFBzR7AAWPEptfjPRVYSb/mkfcKu0JxjKHbA1y0hnttpJSuxsVvgIarK3DkltEtwtWoagtjY7rLhPwDvctDZfmoikQ2t4rQr7kVTFqqafaKzCI5vJ3xbNIBCwwwbrtO4MD+xgAlLALY9iwaRbL8MADCkiAwL8/SHwvxeyhS5MI9XLcMcMfkxZyDA80cEAEmSo887s122ytMAigumm7P/fAcmw3x0CBAgw45HPSPgZNXBUSBJSEyu4uXS0VDaybLdJUa2n1hNYqSuvUZf/g9blU/Cp2qmS3fcPbDlPBrLPQymx3EHiDbMUEyirL9t87BE7g0JhqzS7igJ+tWdMvPGDAAwfE/Djkbku+ocu5HBCo/9+cT+k5ZpS78MA1CiDguJp1lw6D4kJTEQHRUm8ue+Knj6g31LnrvnsOtF8txazI1wr78Lz3rqIUPs0099HMm+08d1M4q33fwldfQ/FoU6EABPIY0Fj33s8A/uTy1hn24X2kMwAC58M8U02drP/5FH7CPD3AsatDMMg3lxO8AwEb44T+UFcFA5gvAq6D3x6+8oxsKG8E1LigJhboOyncbhfqkKAestENC5ogGPH4BAdRYwUHAG9shYAFPAZQPxFEZRQrfB4VrgUBlKUsgHdwgOX08RN//G+D18MeFcK1Cw0CsBD7kMDGjJEAWrwMh0mUEegcOLoWwGQEEGwiC7hGrv8cKnEK82LUEU2wk3C8w1HUwJ9SgJg+E5hRi1ToV89c8BSEIEQFZNzWHauDLlKZymgpeAoFKzICqoiFLHX8XhYJWQWIwaCPvPijCBxpFUhGUn2TTF0LMLYLjb3gKW8EACzkWBc6fnJgoazCyEp2Mhf8ShZhBItjXgnKLIpyBf0DgOaWx8sYDPKXK8jZzvaIvmLmKpY7JBoif/gGTrblmtjMJgFEgYhjWuFpUYNhki4wmHKa85x+uYAr7eDNPL5OhGQgQAEmWYB11qGdU3jf1uypBXnSk59zwKcU0jErJ1IzSfPMYj0TIdAoyA2eY/CnQgEqh4ZCgQIM0B5ExSDRJC7/tJvQnEI2GrfRMHT0eh89hEWfYDnMDZNuQkqoRykah5U2wVeiW2MPAumDkzovpYawaRNWZ4DWvZN6CP0nQ0PqQdyVFAw+7R1QCyHUJoAzeMSEkkxRStPIMLU3Xa1CVE83VUJUdQmjKuhTvzBWz5V1EGdVggxLuVYvtFVybxVEXJEgEwPwra5duOvZ8hqIvSKhqErg6U63+tOwusGwRWAUBEi2NtJ5ibFSdWwbIDuE6PFDpzxQbGgxS1bNsoGzQ3BWRptVQ6RqVakg9WUD2/FS116JtG417RpQKwQKGEAZDkQAaHcgWuLiFq+6VQNvgyARorX2iUmd6FJlyz8JnCmB/5ZVg2CtRlhALJcIVcRuVm8LW5V+FQryo2t207DdoHX3D98NwsiAVcv1oqG9NXuvH+L7A5lkgxk+3Glyn4Dfj+m3D/z1ga8UoM9m3ve4gx1wdqg7hUx9ZQBHhe5rpRvbJCKzBWYS54ZnOl0PWyem5Q3qeb0j4SYUuGEH5kOCeRArJhRXBy82V4z3MGMdLDixLbYxhLkbZNGsmAnKAC4XAcuFHFNrx3rosQ7SK4zh4rjIiR2ye7HcmiM3wbrhFTF5OWxeClPBkkzegpNjBOU8SHkHpASWeG172RRT1ctMmKXJAhxaLkdMy/n1c4LMDIVg1lbDYyZxh6/34RQok2d8Jv+uoAUFaANPGjh4XsJI5zfNnl7aVpWG8aeTk+klXFXMdSazigltnFGnKtQ6dnV0St0gWQMM1k+2dRbebIYb52DNKWozHnhdBl/jANgiEvYdiK0DNNv3DMjWkLKB4NkrzqIWSYkcq58QZ1M+u9e4ZrOuj1JEFBSjH9o28RJJtuc09zPcwR73QpBigmtosmrbvukVD33QEXP1Cjc8iDrunW5Gy1JnkHZ3FqItoWkPYZEj2Icwst25fDdh00VTOBYYriCH+yAuNhwGFQ+C7iLROgmn1vgVOD4gj/dAMf9ozMhFQHCTW1wJsWJA8lRuBZbvx+UVPTl4MfVZnosV3smWd3r/hE4EZe2tWdwbb6oVXWZ1T4ECUsO60ang8/kAvaZMLwJihWnlXyvduHY2a9h7+1vL/bbsxz47jpEubblPgdk1aC4In9vvRP970c5r9AmYcd0501m7dG+43ad1c01LHO43MHbkE9/xxUcB7zaY728jfWUUq/rOjU+Cf38iAc6b3fNU77M2V896scxu7UJYcIOljvi0E28BuM+97nfP+977/vfAX8CKMF8DC+8iw32f+t+VJoDmO//50I++9KdP/eoLYPiwL0KIe3W/XUY39YmzvvjHT/7oYz/0ScgaDnxi+BNI3gZdX8/X7Vj++tt/+ue3uhRmz/2Jj9Hy8Ed5Ladb/wNwfwZogPlncDukNlCDAwG3SWfhSX7XWG5zgBZYfgkYeA1UdDcAcRD4SABYA/E3HvNXAgV4gShYfRnYO4J3Ak/nbDAAcgBQQIAUgjQwgttRgiRwginYg9C3gqfTgkAAc4zxf6i3fFPig0rofEDoOUIYBe8nggL4cwS4hEvYhJLzhFAQhTc4hV5XhVbog1h4NlpIYDY4AzioHTo4AjwYhig4hlZThjR3Jj2EarX3eVrihj0Ih0EjhwDARLrkYNDmhfIHhnp4gXxYM3KYLl1Ee+xFiCRoiId4gIn4MX6YRvzmaUdIgUwyiYj4euiHBHpkenG3iZlVgZ5IiaCof1FwMP+HtHVTkIbUsYYDk4qq6CnZ9wPa81ffVmyQmIOSaIsYuIoKWGgzoV6CCG62FybCeH+V2DBlyCg5I43Ip4nfh4Th14z194zmsoj7Rj69GE+/qIbBqI3Wx43Ucol+xTOQB39nKAOyOB20CABtaI7nSIwaGE3CwHfW6G+cyHz2OH7omCPfxChR54gPtox3E5ACiY8smD27CIOH94gK2SYMKX4DCSTQc4zAAotSEI/MMY/1eJHm55BBOAXS2ADU6JFQOI6zWI4k+XwZeSSgAzPgmIy+WJHfE5PUN5NOIi/r6EAsuYUuKY8wyZPXZ5JOyDi7wI8CZoqlhYpI+YNKmYVWIDr/CnCQMHWN/5iEU0mVuBiKRuAAMpQRdkiReEg8XwmWLkB8MjABEjc/WDWRCZmWzLiWTFiVZJhP9FNFEESKkfeOMQCSyyGSeJmXYcmKTjB2/jOUBFaUIXmUPOmTVVJhFMF/dDmIOpknh9l8lMklIgUsahSICKmZdrmQnfmZY5JH/FCN/TiBp9iJqamXcVhJjMJKOCmOm6k+nZmUiVmMtCGYMECYw2GYs/mb+agawmkKkFmYkhmTqvkmJ8aVsQmQhxmdezKd/lidXnmdtNmH2gmbUSmb3omcD0kiUJlbUomX2Hko4al8XZmN5dmWuXglyxkUzVmcz0mS7Ukp73mH4JeH/8dJn2LJIvfZAsQpHMY5n6xSn15yoGOUnwq6nxfZn6Dyn2gZoGo5oA1aoDQCoTYhobqxoOz5nYqIoTTwRSZwYZhjJyKaGyS6lhbqKigqA21kAgjxAAgEartZKL05o7tSozLQFRj0MnHEo6dpkRzKAm7JVmFFpCEnC0eqJi8aGzH6lUB6LEIaA1AKAEc6pa/Wo8b0oyZqiVt6STxBRKNiC7Swo1QqprNDpuZ5kuiZA7cEACPHorh5a3DqKXJKoIrJYumJXOspo2UKjWcaUVUKG1c6lVnqLYnKUYv6Go2KlI8aL3W6neNpnSU6p0uZqeKpnuTZqYAKnGA1qBFWqFh6qP/dGKkmNamnUamTyarp+J6td6utN5ywahqyCp20SpCgSo/BN6zEWqy8tyIJOqIUypCXqi/vOZKOqqt92pZ/2qGBah6PAa2WKq1JupNL+kweuiPZWq0ROq2sQq7geq3uMa7fCki7Whq9yp+/qpHBqq2zypzmyqToqgJNalfsyqDl2q2c2a4p0K+B9a+kiqDvShrxWqHzSpP1uq9KsbCc0bDM+rA/GbEEWxcUuxkWG5DNWjAaC7Ahmq+5IrEoYLBNhrCGiq8Cy5sbyy0Oql0su6ouq6F3SbL8OrNYkEsGRQL2YK++erPYKKA6W7A820IdCaatZIIo634dqxkfa48hWzH/b+BHJVcCQfu0rBC1mTG15li1LeMGi3Rv1jQWWGEVA2CsbNu2vjcA2mQB5IROdFu3f3EBaYurabG2btu3bgu32ZQXdju4dgu4Z8FNZIC1SXG2eotNFpC3jRu5jfu4klu5lrsWlHu5muu4kLu5p4C4Y5BKq+QEXIigIIqGpysCpfsEPmuG7JW6gwm7qysIs1uD9iG7sHu7r6u70Ja7/pG7tVuKvXsXoZAGxQsKoEsGx+tMzNu8zvu80Bu90ju91Fu91nu92Ju92usFihIa3XsX1LCjNPgEcUlxJJANndYDM9cExuAoMoEAUlC+KoC+RrC+lXAR3TC+TmC/KSCU9Vtu/+zbRO8bvwCsAv5bBPw7CdRQCzwzDBcGFsHgQHI2BOv7FRDQpufwDo1BlsKQAHNxQDMIDkQXRxyMERPwvrBQNBeRtUeAAEkGwgzxDzVhwcYAmDRQwRiBwSKgwTs8Vx4cCyCsC3EkxDRRwhBwwvOTwg6wwuYLCXGkDLXgAAixSgOkSs7wwHuKA3FZE81gDHLUOiOgoxrxwfMTwruQC8JwADqaALcjRWVMQnhawEvgwreTwl5KE21qKmBhDA5wGO1nA1sMAF1sbWAsAmI8AmQMv4eBxme8xm08wHCcwJJgDpu2xC+zKNwgTKT5A/brEzf5h1qTSogMxGVMgwX0Dp81wP+ZLMlI4MJWXMYjpwuZAxb6y8kF7MkksDo73JGj7ABBXA2nLD2qzBOs7MTDsBNSzAtUzBMeCAT2u8A0JAK3wz2HHHIH8MvnQIM6mjvD3A3GMJdJ4MrJUMZxlMeLVMs+8Mwz1BjTHMYZZ83YHKWGHEJHAb+rPADgHAn5gMqycGEI8AyZ3My2PHFfIUW1AC0QIDYl/BMSYcemXA0L3QDd7A8sXL/w6w/wG8PAMsO0bBDOjBQFbUUIrdA+3NClDMwQPVcSXcaZPFJN3CMTsMlNEdM/+0rp8Mc5cdPbu9M83dMCLQboHAdBDQZDnRM/rRMePQdF7QVL7RJHTdRJLQdNzQX/U90JuYRASQwPDFAL4fDAz0BBEZwARozECAALOA0rExHBugABI/UMGt2ic/EV3RABi9ENat2OQPDAOgMsa93WCyFDcB0Lcg0AdL0Lds3XeP0Ceq3WGOHXb10Tcc0Thc0Td50J7ys1kIxhf4jPU0wTiyJcQOHIGOZZZ50svAwAVQwLERDT8VDOa6wLg51KzRABzZXYPRDBI5DaNMTad6wsr20LPCHbNFTbQIDb24ARVrza8NDbeQzbwd2Rs03cmXAp4JDZtzAXR7ooDxwQqFxlAxwEGu0MmVzOsFxEsnwYUrFpu6AAmdyKc5VRPEHe8BvLRNeUFD1x7U1t7z3eeFze/0Bx3vt43+ud35swziCMEHPR2bPMADe0zchQxk0HD/ytLOSMx799AC48AaJ83DYc4ZgT3/0Nv66NQLKc4RuO2mmaWhIO4hQu4hZO4jRh4qeN4h2eCN39z9Ydwv0MQl/tDHCpDhH93UCwaX414QOs0X6l47fjKJMt3in+BETeLCx+5DKU5HOx5IS9GE5e4y8Q5UZexkgO2bGA5U0O31ze02ie5mq+5mze5m7+5nAe53I+53Re53Z+53ie53q+53ze537+54D+vDF80S7xQTW9MKh8CwR+Ak9tQi2QpzINCd0d1fqQQiyAEEJOKN3tAIseA1+RxSdQzJKQ6SXQVy5Qc/+R8g614FfBvRNHfL7OgMKctmkKkAAX0aKTnSkTZ0K5dNgS7G2H8N00TMwdPNndYOvCoN7JkNGALebi8iHz0Ayw0A1r/A1iY0GZ3Q1fShOs/UYJNHIWlErsoNuH7gfCvsek7CjCHQEZRHLt4Moj/sMU8A2E/iDzYEXgkErsR3JnwtIsHsf8cG/g7gwIEcEBHemCcO7PQMaOot62sL5/5Mr0jcYOQOoAYhQSQe0IZO2w3u/2/O/UcD7eHnH47A8MIO62cPDl3gcKr+OpdOLtTnOajacu7tswXvEQfiFPQQ3d0Me78Or8PtFHiuwglOV05dK8HkU0rskrvweT7kId7ctEvFzmRI/HO7Hsf11KYo7z9R7oXv/1YB/2Yj/2ZF/2Zn/2aJ/2ar/2bN/2bv/2cB/3cj/3dF/3dn/3eJ/3er/3fE8FIQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a random population of 516 men and women between the ages of 50 and 79, those with endotoxin levels &gt;50 pg/mL (90th percentile) had a threefold increase in risk of carotid atherosclerosis. The risk associated with high serum endotoxin was most pronounced in subjects with chronic infections and in current and ex-smokers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Wiedermann CJ, Kiechl S, Dunzendorfer S, et al. J Am Coll Cardiol 1999; 34:1975",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39741=[""].join("\n");
var outline_f38_51_39741=null;
var title_f38_51_39742="C ANCA";
var content_f38_51_39742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F66748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F66748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    C-ANCA pattern on indirect immunofluorescence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Demonstration of cytoplasmic antineutrophil cytoplasmic antibodies (C-ANCA) by indirect immunofluorescence with normal neutrophils. There is heavy staining in the cytoplasm while the multilobulated nuclei (clear zones) are nonreactive. These antibodies are usually directed against proteinase 3, and most patients have granulomatosis with polyangiitis (Wegener&rsquo;s).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39742=[""].join("\n");
var outline_f38_51_39742=null;
var title_f38_51_39743="Haemophilus 2";
var content_f38_51_39743=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Haemophilus influenzae in cerebrospinal fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <em>",
"     Haemophilus",
"    </em>",
"    spp. under high power magnification (1000x) in CSF.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_51_39743=[""].join("\n");
var outline_f38_51_39743=null;
